Welcome to #ASTRO17 1 by Brian D

Home , How We Do (Party)

ISSUE 59th Annual Meeting | September 24–27, 2017 No. SUN & MON Welcome to #ASTRO17 1 By Brian D. Kavanagh, MD, MPH, FASTRO, ASTRO President

he ASTRO Annual Meetings are each like a separate see it. My growing sense was that, with so much potential for chapter in our field’s ongoing narrative. Some storylines upheaval in the structure of medical care delivery and the rela- Tadvance, some familiar faces reappear—but a few plot tionships among stakeholders (patients, providers and payers), twists also spring up, and some new characters emerge. All of it would be timely if we re-examined some core principles and us together are writing the story, and on one level I view my refreshed our outlook on how we do things, what we like about role in the process as this year’s editor-in-chief. our specialty and what we should think about in the future. Last year, David C. Beyer, MD, FASTRO, called attention to My hope is that you leave this Annual Meeting with these our place in the evolving landscape of health policy across the goals accomplished. To help you fulfill this, I’ve created “crib entire house of medicine, a theme he was especially well-qual- notes” of a sort to guide you through my chapter in our special- ified to craft given his deep fund of knowledge and expertise ty’s tome. With that in mind, here are the top five things not to in this area. For 2018 (spoiler alert!), I anticipate that a physi- miss at this year’s Annual Meeting, in no particular order. cian-scientist extraordinaire like Paul Harari, MD, FASTRO, will capitalize on his bench-to-bedside brilliance to showcase cut- 1. Presidential Symposium. ting-edge innovations that have the potential to transform our This event will capture the essence of the meeting’s overall methods of cancer treatment. Thus, the question for a dilettant- theme, “The Healing Art and Science of Radiation Oncology.” We Keep your Annual Meeting schedule organized, even on the go ish, jack-of-all-trades, master-of-none charlatan like me was this: will try to generate excitement for the creative sparks that are What is the place in between those two places? What should we moving the field toward new paradigms in translational research talk about right now? Where in the storyline are we? and clinical practice in the first session, “The Scientific State Use the The advantage to being anxious, insecure and prone to of the Art.” Next, in “The Art of Quality,” we start a conversa- bouts of existential terror is that I think I know anomie when I tion about how we should identify hallmarks of quality care in ASTRO Online radiation oncology and track them—a topic that is Conference crucially important and sounds simple but is much trickier to wrap our heads around than it seems. Planner and Finally, we arrive at “The Quality of Mercy,” where we will look into the soul of our field. We’ll also Mobile App to have a little fun along the way with cameo appear- Plan Your Day ances from some famous radiation oncologists of Customize your Annual Meeting experi- artistic renown. Read more about the Presidential ence with the Online Conference Planner Symposium on page 8. and ASTROmobile17, the official app for the 2017 Annual Meeting. You can: 2. ASTRO Connect booths. ✓✓Search sessions by day, track or speaker. These five booths, located in different areas of the Innovation and Solution Showcase (former- ✓✓Search and view full abstracts. ly the Exhibit Hall), will each have a different ✓✓Search exhibitors by name, booth focus—breast, GI, GU, lung and physics. Meeting number or product/service category. attendees can stop by to view top-rated posters, ✓✓Set up and access your personal Annual recharge electronics and network. The Connect Meeting schedule via “My Schedule.” Brian D. Kavanagh, MD, MPH, FASTRO, at the ASTRO headquarters in Arlington, Va. Continued on page 4 ✓✓Take notes on sessions or exhibitors and access notes from your mobile device. ✓✓Access the CE evaluation tool to complete session evaluations and receive Caption San CE credits. Diego ✓✓View convention center maps and locate sessions and exhibitors with City customized maps.

The Online Conference Planner and Guide ASTROmobile are fully integrated so you included can access your up-to-date customized notes, maps and schedule from both. inside!

Download ASTROmobile for free in the App Store or Google Play Store on your IOS or Android device. Other smartphone users can access the mobile-friendly site at www.astro.org/astromobile. Access the Online Conference Planner at www.astro.org/conferenceplanner. Connect with Accuray at ASTRO BOOTH #1517 Or visit www.accuray.com/astro17

#ASTRO17

CyberKnife® Radixact™ Treatment Delivery System Treatment Delivery System Automatically tracks and adjusts to target motion A major step forward in the evolution of the during treatment with sub-millimeter accuracy. TomoTherapy® System in treatment speed and ease of use.

iDMS™ Accuray Precision™ Data Management System Treatment Planning System Common database for seamless management of patient data Centralized planning and control for all Accuray Systems across multiple Accuray Systems and clinics.

© 2017 Accuray Incorporated. All Rights Reserved. Important Safety Information Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury, and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), and the patient’s general medical condition, to name a few. For more details about the side effects of your radiation therapy, and to see if treatment with an Accuray product is right for you, ask your doctor. MKT-ARA-0716-0106(1)

Accuray_ASTRO-Dailies_2017.indd 1 8/29/17 10:33 AM ASTRO DAILY NEWS | Sunday/Monday

SCHEDULE AT A GLANCE Do You Have the Sunday, September 24, 2017 Next Big Idea? By Emily Connelly, MA, ROI Governance 6:45 a.m. – 8:00 a.m. 12:15 p.m. – 1:15 p.m. 2:45 p.m. – 3:15 p.m. Connect with Accuray at International Welcome Breakfast Nurses’ Welcome Luncheon ASTRO Connect Meet the Expert and Research Administrator and Judy Room: 6A; 1.25 CME Room: 26 A/B; 0 CME Physics: Booth #530 – Søren Bentzen, DSc, PhD Keen, PhD, Director of Scientific Affairs Ticketed Event Breast: Booth #405 – Bruce Haffty, MD, FASTRO ASTRO BOOTH #1517 7:45 a.m. – 8:00 a.m. GI: Booth #3021 – Bruce Minsky, MD, FASTRO The Annual Meeting brings together some Booth #3739 – David Beyer, MD, FASTRO Welcome to San Diego, – Prabhakar 12:15 p.m. – 1:15 p.m. GU: of the best and brightest minds in the world ARRO Annual Luncheon Lung: Booth # 3709 – Kenneth Rosenzweig, MD, Tripuraneni, MD, FASTRO, who aim to advance the field of radiation Room: Ballroom 20; 0 CME Room: 29 A/B/C/D; 0 CME FASTRO Or visit www.accuray.com/astro17 Ticketed Event oncology. ASTRO and the Radiation 8:00 a.m. – 12:15 p.m. 3:15 p.m. – 4:45 p.m. Oncology Institute (ROI) want to harness Clinical Trials Session Presidential Symposium – The Healing Art 1:15 p.m. – 2:45 p.m. the collective brainpower assembled to and Science of Radiation Oncology Poster Viewing Q&A – Tracks: GU, Biology Ballroom 20; 1.50 CME Opening Remarks Brian D. Kavanagh, MD, MPH, Room: Poster Hall, Hall A-B1; 0 CME answer two pressing questions for the field. FASTRO 4:45 p.m. – 5:45 p.m. Room: Ballroom 20 1:15 p.m. – 2:45 p.m. ARRO Meet the Professor Reception How do we improve our ability to get #ASTRO17 Scientific Sessions; 1.50 CME Room: 28 A/B; 0 CME radiation to the patients who need it? 8:00 a.m.– 9:10 a.m. Ticketed Event • SS 01 – Breast 1 – General Outcomes and Presidential Symposium I – The Scientific Toxicity, Room: 3 What is the most important research State of the Art, Moderator: Robert D. Timmerman, 4:45 p.m. – 6:15 p.m. MD • SS 02 – HSR 2 – Health Services Highlights, Poster Viewing Q&A 2 – Tracks: Non- question that needs to be answered in Room: Ballroom 20, 1.25 CME Room: 7 A/B malignant, Palliative, Patient Reported Outcomes, the next three to five years? Patient Safety, Informatics, Health Services Research • SS 03 – Physics 1 – Imaging for Response 8:00 a.m. – 9:30 a.m. Room: Poster Hall, Hall A-B1; 0 CME Assessment Using CT or PET, Room: 31 A/B/C Focused on funding research to heighten eContouring Session 03 – eContouring for 4:45 p.m. – 6:15 p.m. the critical role of radiation therapy in the Breast II and CNS Cancer 1:15 p.m. – 2:45 p.m. Room: 25 A/B/C; 1.50 CME Scientific Sessions; 1.50 CME treatment of cancer, the ROI wants to know: 1.50 CME Ticketed Event ePoster Sessions; • SS 04 – Lung 1 – SBRT, Room: 8 How can we improve our ability to get • eP 01 – CNS ePoster Discussion 1 – Brain 9:10 a.m. – 10:15 a.m. Metastases, Room: 5A • SS 05 – Biology 1 – Innovative Biologic radiation to the patients who need it? Presidential Symposium II – The Art of • eP 02 – Physics ePoster Discussion 1 – Treat- Approaches to Improve Risk Stratification and Responses to the question will be used to Quality, Moderator: Najeeb Mohideen, MD, FASTRO ment Planning, Room: 5B Treatment Outcomes, Room: 7 A/B inform the ROI’s research plans and could Room: Ballroom 20; 1.00 CME • SS 06 – GYN 1 – Cervical Cancer, Room: 11 A/B 1:15 p.m. – 2:45 p.m. be used to develop a future request for 10:00 a.m. – 5:00 p.m. 1.50 CME proposals (RFP). Your input will help the Panels; 4:45 p.m. – 6:15 p.m. Exhibit Hall Open • Panel 01 – Female Sexual Health and Cancer: ePoster Sessions; 1.50 CME ROI to fuel innovation that addresses the What Every Radiation Oncologist Should Know, practical needs of radiation oncology in the 10:00 a.m. – 6:15 p.m. • eP 03 – Hematologic ePoster Discussion, Room: Room: 11 A/B changing health care landscape. You can Poster Viewing 5A • Live SA-CME – Panel 02 – Why Smart People share your ideas with the ROI by submitting Do Dumb Things: Decision Making, Bias and • eP 04 – Physics ePoster Discussion 2 – Out- 10:15 a.m. – 10:30 a.m. your response at ROI’s booth (3639) in the Medical Error, Room: 6B, Ticketed Event come Analysis and Modeling, Room: 5B Break Innovation and Solution Showcase, in any 1:15 p.m. – 2:45 p.m. 4:45 p.m. – 6:15 p.m. of the ASTRO Connect locations or online at 10:30 a.m. – 10:45 a.m. Educational Sessions; 1.50 CME Panel Sessions; 1.50 CME – Special www.roinstitute.org/amquestion. Presidential Symposium • Panel 03 – Controversies in the Treatment Introspective Interlude, Anthony Zietman, MD, • Interactive – EDU 01 – Challenging Cases in GI Annual Meeting attendees are also the Malignancies, Room: 30 A/B/C of Benign CNS Tumors: A Case-based Panel FASTRO Session, Room: 2 perfect audience to ponder the Million Gray Room: Ballroom 20; .25 CME ® ™ • Interactive – EDU 02 – The Top 10 Pitfalls in Question: What is the most important CyberKnife Radixact Clinical Trial Design with Radiation-Drug Com- • Panel 04 – MRI-guided Adaptation: From Anato- Treatment Delivery System Treatment Delivery System 10:30 a.m. – 12:00 p.m. binations: Perspectives from Industry, NCI and my to Biology, Room: 3 research question that needs to be an- eContouring Session 04 – eContouring for FDA, Room: 6A swered in the next three to five years? As Pediatric Cancer and SBRT/Spine Cancer 4:45 p.m. – 6:15 p.m. Automatically tracks and adjusts to target motion A major step forward in the evolution of the • EDU 03 – Metabolic Imaging in Cancer, Room: 8 cancer researchers conducting cutting-edge ® Room: 25 A/B/C; 1.50 CME Education Sessions; 1.50 CME during treatment with sub-millimeter accuracy. TomoTherapy System in treatment speed and ease of use. Ticketed Event • Interactive EDU 04 – Primer on Tumor Immu- research, who better to provide the answer • Interactive – EDU 05 – Challenging Cases in nology for Radiation Oncologists, Room: 30 D/E the Management of Breast Cancer, Room: 6A to this question than ASTRO members? Your 10:45 a.m. – 11:58 a.m. insight can help shape the future of cancer 1:15 p.m. – 2:45 p.m. • Interactive – EDU 06 – Challenging Cases in Presidential Symposium III – The Quality of research. What gap must be filled? What Mercy, Moderator: Stephen T. Lutz, MD eContouring Session 5 – eContouring for the Management of Newly Diagnosed and Recur- Room: Ballroom 20; 1.50 CME Head and Neck Cancer I rent Prostate Cancer, Room: 6B data has yet to be generated? What do we Room: 25 A/B/C; 1.50 CME need to learn? 4:45 p.m. – 6:15 p.m. 11:00 a.m. – 2:30 p.m. Ticketed Event Answers to the Million Gray Question ASTRO Bistro Open International 03 – Implementation of 1:15 p.m. – 2:45 p.m. Prospective Multidisciplinary Tumor Board to can be shared through the icon on the 11:58 a.m. – 12:15 p.m. International 02 – ASTRO/ESTRO: Cutting Optimize Each Individual Patient Care ASTROmobile app or at any of the ASTRO Room: 31 A/B/C; 1.50 CME Presidential Symposium Finale – Stephen Edge Combined Modality Therapies (Focus on Connect locations. All responses will be NSCLC) T. Lutz, MD, FASTRO and Mystery Guest on display on screens throughout the Room: Ballroom 20; .25 CME Room: 2; 1.50 CME 4:45 p.m. – 6:15 p.m. Interactive – Joint Session 01 – ASTRO- meeting. 12:15 p.m. – 1:15 p.m. 1:15 p.m. – 2:45 p.m. SITC Joint Session: Clinical Implications of New “The people who are treating cancer Lunch Break Young Physicians Workshop – Session 1 Findings on the Immunogenic Effects of Radiation patients every day are an ideal source for Room: 4; 1.50 CME Room: 30 A/B/C; 1.50 CME inspiration about how to improve practice,” ™ ™ iDMS Accuray Precision 2:45 p.m. – 3:15 p.m. 4:45 p.m. – 6:15 p.m. says ROI President Deborah A. Kuban, Break eContouring Session 06 – eContouring for MD, FASTRO. “We’re looking forward to Data Management System Treatment Planning System Head and Neck Cancer Room: 25 A/B/C; 1.50 CME receiving responses from every member of Common database for seamless management of patient data Centralized planning and control for all Accuray Systems Ticketed Event the radiation oncology team.” across multiple Accuray Systems and clinics. 4:45 p.m. – 6:15 p.m. Submit your answers today! ASTRO Daily News 2017 Young Physicians Workshop – Session 2 Issue Number 1, Sunday/Monday Edition Room: 4; 1.50 CME Publisher: Design/Production: Contributing Editors: © 2017 Accuray Incorporated. All Rights Reserved. Laura I. Thevenot American Medical Communications Beatriz Amendola, MD, FASTRO Stay up to date on the Meeting! Important Safety Information Francine Pozzolano Kerri Fitzgerald Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, Editorial Director: Ari Mihos Miriam A. Knoll, MD however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury, and even death. Side effects can occur Anna M. Arnone Christian Okoye, MD during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the J. Ben Wilkinson, MD #ASTRO17 treated tumor, the treatment technique (for example, the radiation dose), and the patient’s general medical condition, to name a few. For more details about the side effects of your radiation Managing Editor: therapy, and to see if treatment with an Accuray product is right for you, ask your doctor. MKT-ARA-0716-0106(1) Leah Kerkman Fogarty See Monday’s schedule on next page

Accuray_ASTRO-Dailies_2017.indd 1 8/29/17 10:33 AM ASTRO DAILY NEWS | Sunday/Monday

WELCOME continued from page 1 SCHEDULE AT A GLANCE booths are a new feature this year, and they will provide opportunities for attendees to meet and learn from one another Monday, September 25, 2017 and from topic experts in an informal, collegial atmosphere. See the story and a Meet the Expert schedule for each of the 7:45 a.m. – 8:15 a.m. 10:45 a.m. – 12:15 p.m. 2:15 p.m. – 3:45 p.m. Science Highlights – Genitourinary Poster Viewing Q&A 3 – Tracks: Plenary Session five ASTRO Connect booths on page 15. Room: 11 A/B; 0.50 CME Breast, GYN, Nursing Room: Ballroom 20; 1.50 CME Room: Poster Hall, Hall A-B1; 0 CME 3. Keynote speeches. 7:45 a.m. – 9:00 a.m. 3:45 p.m. – 4:15 p.m. ASTRO Grant Awardee Network- 10:45 a.m. – 12:15 p.m. Break First up, on Monday, Richard D. Zane, MD, Chief Innovation ing Breakfast Oral Scientific Sessions; 1.50 CME 3:45 p.m. – 4:15 p.m. Officer for UCHealth, will discuss how disruptive new technol- Room: 28 A/B; 0 CME • SS12 – Head and Neck 1 – Chemo- ogy has begun to restructure front-line patient doctor rela- Ticketed Event radiation for Head and Neck Cancer, ASTRO Connect Meet the Expert Room: 7 A/B Physics: Booth #530 – Martha Matuszak, tionships. I personally know Rich well and promise a clever, 7:45 a.m. – 9:00 a.m. PhD • SS13 – Physics 3 – Best of Physics, thought-provoking and highly entertaining presentation. Oral Scientific Sessions; 1.25 CME Breast: Booth #405 – Catherine Park, MD Room: 31 A/B/C GI: Booth #3021 – Karyn Goodman, MD, When the Annual Meeting Steering Committee solicited • SS 07 – Physics 2 – Outcome Analysis and Modeling 1, Room: 30 D/E • SS14 – Biology 3 – Innovative Biologic MS suggestions last year for Keynote speakers, Jona Hattangadi- Approaches II, Room: 30 D/E GU: Booth #3739 – Theodore DeWeese, • SS 08 – HSR 1 – Health Care Costs, MD, FASTRO Gluth, MD, proposed Lucy Kalanithi, MD, the widow of the Room: 5A 10:45 a.m. – 12:15 p.m. Lung: Booth #3709 – Percy Lee, MD late Paul Kalanithi, MD, who authored the national bestseller, • SS 09 – Patient Reported Outcomes, ePoster Sessions; 1.50 CME “When Breath Becomes Air.” We immediately saw Jona’s idea Room: 5B 4:15 p.m. – 5:45 p.m. • eP 05 – CNS ePoster Discussion 2 – Poster Viewing Q&A – Track: Physics ASTRO 2017 – Pediatrics 1, Room: 26 A/B as a stroke of genius. Quynh-Thu Le, MD, FASTRO, helped us • SS10 Glioma and Benign CNS Conditions, Room: Poster Hall, Hall A-B1; 0 CME connect with fellow Stanford physician Dr. Kalanithi and, as • SS11 – Biology 2 – DNA Repair and Room: 5A MEET LAP Damage Response, Room: 4 • eP 06 – GI ePoster Discussion, Room: 5B 4:15 p.m. – 5:45 p.m. AT ASTRO a bonus, coaxed Heather Wakelee, MD, Paul’s oncologist, into Oral Scientific Sessions; 1.50 CME joining her onstage for a “fireside chat” about Paul’s journey 7:45 a.m. – 9:00 a.m. BOOTH 2037 10:45 a.m. – 12:15 p.m. • SS 15 – Breast 2 – Altered Fraction- through lung cancer treatment. Education Sessions; 1.25 CME Panels; 1.50 CME ation, Predictors and Biology, Room: 29 A/B/C/D We can thank Charles Thomas, MD, for brokering a connec- • EDU 07 – Evolving Paradigms in • Panel 05 – Stereotactic Body Radio- Hypofractionation and APBI, Room: 31 tion with Wednesday’s speaker, Vinay Prasad, MD, of Oregon therapy for Early Stage Non-small Cell • SS 16 – Pediatrics 2, Room: 3 A/B/C Lung Cancer: ASTRO Clinical Practice • SS 17 – Hematologic 1 – Innovation in Health & Science University, one of the freshest and liveliest • Interactive - EDU 08 – Cancer of Guideline Recommendations and Evi- dentiary Base, Room: 29 A/B/C/D Techniques and Overcoming Challenges, new voices in oncology. Dr. Prasad co-authored the bestseller, the Colon, Rectum, Anus, Room: 29 Room: 26 A/B “Ending Medical Reversal,” and is a frequent commentator A/B/C/D • LIVE SA-CME – Panel 06 – Are You Down with the QPP? You Better Be if in national news media on the topic of waste and inefficiency • EDU 09 – Management of Oropharynx 4:15 p.m. – 5:45 p.m. Cancer: Optimal Treatment and You Want $, Room: 6 D, ePoster Sessions; 1.50 CME in health care and shortcomings in our system of medical Strategies for Toxicity Reduction, Ticketed Event • eP 07 – Physics ePoster Discussion Room: 7 A/B research. Dr. Prasad’s iconoclastic take on a few hot button • Interactive – Panel 07 – Radiation for 3 – Imaging for Response Assessment, issues in oncology will leave you wishing we could give him • EDU 10 – 2018 Radiation Oncology My Lymphoma Patient: How to Explain Room: 5B Coding and Reimbursement Update, the Care and Defuse the Scare?, Room: 3 • eP 08 – Biology ePoster Discussion 1 – another hour on stage. And if you are on Twitter, I strongly Room: 8 Translational Radiobiology, Room: 5A recommend following @VinayPrasad82. 10:45 a.m. – 12:15 p.m. • Interactive – EDU 11 – Pain, Palliative Education Sessions; 1.50 CME Be sure to check out Tuesday’s edition of the ASTRO Daily Care and the Opioid Crisis: What is the 4:15 p.m. – 5:45 p.m. Provider Role? Room: 30 A/B/C • Interactive – EDU 12 – Is There a Panels; 1.50 CME News for interviews with Dr. Kalanithi and Dr. Wakelee, as “Best” Way to Manage Respiratory • Panel 08 – Biology of Breast Cancer: well as one with Dr. Prasad. 7:45 a.m. – 9:00 a.m. Motion?, Room: 30 A/B/C From Bench to Bedside, Room: 8 Interactive – International 04 • EDU 13 – Radiotherapy for Locally – Global perspectives on Challenging Advanced and High-risk Skin Cancer, • Interactive – Panel 09 – 4. Presidential Address. Cases in Radiation Oncology: Snapshot Room: 6A Management of Hepatic mCRC and On Monday afternoon, from 1:30 p.m. until 2:15 p.m., I will of Breast, Lung, and Cervix Cancer from HCC Tumors: A Multidisciplinary • EDU 14 – Translating Hypofraction- Tumor Board, Room: 11 A/B take the stage in Ballroom 20 for the annual Presidential Ad- Your Local Clinic to Site-specific Thought Leaders ation Trials in Prostate Cancer to dress, with this year’s title, “Effort’s Bounty and Other Imagin- Room: 3; 1.25 CME Clinical Practice, Room: 6B 4:15 p.m. – 5:45 p.m. Education Sessions; 1.50 CME ings of Past and Future.” Expect a bit of poetry, a bit of science 10:45 a.m. – 12:15 p.m. 8:30 a.m. – 9:00 a.m. – Management and maybe even a magic trick or two as I use an individual pa- Interactive – International 05 – • Interactive – EDU 15 Science Highlights – Lung Cancer and Contouring of Head and Neck Can- Managing Acute and Late Side Effects in a tient’s story to help frame a few personal reflections and some Room: 11 A/B; 0.50 CME cers with Perineural Invasion, Room: 6B Resources Constrained Environment larger narratives that have characterized the field of radiation Room: 11 A/B; 1.50 CME – Challenging 9:00 a.m. – 9:15 a.m. • Interactive – EDU 16 oncology in recent times. Lung Cancer Cases, Room: 6C Break 10:45 a.m. – 12:15 p.m. • Interactive – EDU 17 – Challenging CNS eContouring Session 07 – 9:15 a.m. – 10:15 a.m. Cases: 2016 WHO Update, Room: 6D 5. Plenary and Clinical Trials Sessions. eContouring for GI Cancer Keynote I: Richard D. Zane, MD; Sunday’s Clinical Trials Session, held in Ballroom 20 from Room: 25 A/B/C; 1.50 CME • Live SA-CME – EDU 18 – Advances in Introduction by Shilpen Patel, MD Ticketed Event Endometrial Cancer, Room: 31 A/B/C, 3:15 p.m. to 4:45 p.m., will be moderated by Benjamin Movsas, Room: Ballroom 20; 1.00 CME Ticketed Event MD, FASTRO, and Lisa Kachnic, MD, FASTRO. These very able 11:00 a.m. – 2:30 p.m. 10:00 a.m. – 5:00 p.m. ASTRO Bistro Open 4:15 p.m. – 5:45 p.m. leaders have helmed the selection of several scientific findings Exhibit Hall Open International 06 – Global Collabora- that focus on some of the hottest topics in radiation oncology, 12:15 p.m. – 1:30 p.m. tion in Clinical Trials: Opportunities and MR3T LASER SYSTEMS IN RT including circulating tumor DNA analysis, combined modality 10:00 a.m. – 6:45 p.m. Lunch Break Challenges Poster Viewing Open Room: 7 A/B; 1.50 CME treatments, immunotherapy and more. 12:15 p.m. – 1:30 p.m. ESSENTIAL FOR PRECISE PATIENT ALIGNMENT 4:15 p.m. – 5:45 p.m. Following the Presidential Address on Monday afternoon, the 10:15 a.m. – 10:45 a.m. ARRO Poster Walk with a Profes- Break Joint Session 02 – ASTRO-SPRO Joint Plenary Session will highlight the cutting-edge science impacting sor (Residents Only) Session: Mythbusting in Palliative Radiation Room: Poster Hall, Hall A-B1; 0 CME the field of radiation oncology. This year, three of the presenters 10:15 a.m. – 10:45 a.m. Oncology: Overcoming Barriers to Shorter Ticketed Event submitted late-breaking abstracts, so attendees will be hearing ASTRO Connect Meet the Expert Course Palliative Radiation Therapy DORADOnova MR3T Room: 30 D/E; 1.50 CME Physics: Booth #530 – Indrin Chetty, 12:30 p.m. – 1:30 p.m. ESSENTIAL AND COMFORTABLE the very latest results from clinical trials. Dr. Movsas and Dr. PhD, MS AAWR/ASTRO Luncheon Kachnic, as Chair and Vice-chair of the Annual Meeting Scientific Breast: Booth #405 – Julia White, MD, 4:15 p.m. – 5:45 p.m. Room: 6C/F; 0 CME APOLLO MR3T FASTRO eContouring Session 08 – Committee, will again be moderating the Plenary Session. Ticketed Event GI: Booth #3021 – Lisa Kachnic, MD, eContouring for Prostate Cancer ESSENTIAL AND ELEMENTARY FASTRO Room: 25 A/B/C; 1.5 CME 1:30 p.m. – 2:15 p.m. I hope you’re able to connect with us at these not-to-miss GU: Booth #3739 – Colleen Lawton, MD, Ticketed Event FASTRO Presidential Address: Effort’s Bounty sessions and booths! ● and Other Imaginings of Past and Future, 5:45 p.m. – 6:45 p.m. Brain D. Kavanagh, MD, MPH, FASTRO Poster Viewing Reception Room: Ballroom 20; 0.75 CME Room: Poster Hall, Hall A-B1; 0 CME

4 ASTRO DAILY NEWS | Sunday/Monday

CancerLinQ Is Community By Sameer Keole, MD, Mayo Clinic, ASTRO Board of Directors

STRO is partnering with CancerLinQ LLC—a many situations where radiation is used, and in some wholly owned nonprofit subsidiary of the Ameri- cases, where radiation is not used. Acan Society of Clinical Oncology (ASCO)—to bring As an official partnering organization of Cancer- radiation oncology expertise to this rapid learning LinQ, ASTRO had the opportunity to be a founding system and improve the care of cancer patients nation- member of the CLQ Oncology Leadership Council the OLC and ensuring that all partners’ perspectives, wide. ASTRO will provide guidance for the develop- (OLC), a body of thought leaders and oncology-affiliat- including those in radiation oncology, are heard. ment of the CancerLinQ (CLQ) platform to ensure that ed experts that advises the CancerLinQ Board of Gov- The partnership reflects CLQ’s goal to create a the system captures more relevant patient data for the ernors. I have the honor and responsibility of Chairing system that encompasses all of cancer care by bring- ing together expertise throughout the cancer community, as well as ASTRO’s vision that radiation oncology be the recognized quality and value leader in multidisciplinary cancer care. “By combining ASTRO’s domain-specific ASTRO 2017 knowledge with CancerLinQ’s broad reach, we can help physicians and their patients be more MEET LAP informed as they navigate complex treatment AT ASTRO decisions,” said Laura Thevenot, ASTRO Chief BOOTH 2037 Executive Officer.

“CancerLinQ is becoming a community that learns together to improve patient care.”

Clifford A. Hudis, MD, Chief Executive Officer of ASCO and Chairman of the Cancer- LinQ Board of Governors, emphasized that “CancerLinQ is becoming a community that learns together to improve patient care.” So how does CancerLinQ work? Each par- ticipating practice’s electronic health records (EHR) is connected to the CancerLinQ database so that clinical data and, in some cases, administrative and financial data can be extracted. The CancerLinQ platform allows oncology practices to ana- lyze detailed information about their own patients while giving them access to

de-identified data for every Sameer Keole, MD other patient in the network. Over time, these analytics will produce insights into practice patterns, outcomes, cost MR3T LASER SYSTEMS IN RT effectiveness and safety issues. CLQ provides a tightly integrated data collection, filtering, ESSENTIAL FOR PRECISE PATIENT ALIGNMENT curation and reporting platform. CLQ also has trained clinical staff who review and curate data from unstructured text documents supported by natural language processing tools as DORADOnova MR3T an additional quality measure. ESSENTIAL AND COMFORTABLE To date, more than 100 health systems and APOLLO MR3T 2,000 oncologists are involved in the network, ESSENTIAL AND ELEMENTARY and it now includes a rapidly growing database of about 500,000 patients with a primary or secondary diagnosis of cancer. Stay tuned for opportunities for how your practice can participate in this community of learning. ●

5 ASTRO DAILY NEWS | Sunday/Monday

New to #ASTRO17: Science Highlight Sessions By Lisa A. Kachnic, MD, FASTRO, Annual Meeting Scientific Com- Located in the Innovation and Solution Showcase (Exhibit Hall) mittee Vice-chair

n behalf of ASTRO, I am excited selected tracks (genitourinary, lung, Sunday’s Monday’s to introduce a new feature to head and neck, central nervous system, Othe Annual Meeting: Science gastrointestinal and breast cancers). Menu Menu Highlight Sessions. These 30-minute ses- An expert discussant will cover the top sions will be held Monday, Tuesday and four to five abstracts from each of these SALADS SALADS Wednesday mornings in Room 11 A/B. tracks in a “best-of” format, allowing at- California Garden Salad California Garden Salad With more than 2,800 abstracts tendees to hear about the latest science, | | scheduled to be presented at this year’s even if they are unable to attend the Shredded Carrots, Shredded Red Shredded Carrots, Shredded Red Annual Meeting, it’s challenging for scheduled abstract presentation. Cabbage, Grape Tomatoes, Cabbage, Tomatoes, Bell Peppers and attendees to get to all of the latest sci- After attending a Science Highlight Cucumbers and Red Radishes Garbanzo Beans ence across all disease sites. I person- Session, attendees will also be able with a choice of Assorted Dressings with a choice of Assorted Dressings ally become overwhelmed when there to hear the full abstract presentation are several ‘must’ sessions that occur by the author either on-site, if it has Orzo Pasta Salad Broccoli Salad | at the same time. To address this issue, not already been presented, or on the With Raisins and Carrots Toasted Pine Nuts and Balsamic Vinaigrette Dressing the Annual Meeting Scientific Com- Virtual Meeting, which is available to all mittee devised the Science Highlights attendees approximately 24 hours after ENTREES ENTREES Sessions to present the top-reviewed each session is completed. abstracts in an easily digestible format. We hope you find this new feature a Pan Seared Chicken Breast All Natural Sirloin For this year’s meeting, there will welcome addition to the ASTRO Annual Slow-roasted with Crimini Mushrooms Marinated in Lemon and Extra Virgin be Science Highlights Sessions in six Meeting. ● and Caramelized Onion Ragout with Olive Oil with White Wine Caper Béarnaise Sauce Reduction Monday, September 25, 2017 Track Science Highlights 1 7:45 a.m. - 8:15 a.m. Genitourinary Ravioli Science Highlights 2 8:30 a.m. - 9:00 a.m. Lung Cancer Vegetarian Gourmet Flatbread With Pesto Cream Sauce With Tomato, Olive, Grilled Artichokes, Tuesday, September 26, 2017 Track Goat Cheese and Fresh Herbs SIDES Science Highlights 3 7:45 a.m. - 8:15 a.m. Head and Neck Science Highlights 4 8:30 a.m. - 9:00 a.m. Central Nervous System SIDES Yukon Gold Mashed Potatoes Wednesday, September 27, 2017 Track | Science Highlights 5 7:45 a.m. - 8:15 a.m. Gastrointestinal Steamed Jasmine Rice and Orzo Science Highlights 6 8:30 a.m. - 9:00 a.m. Breast Cancer Medley Chef’s Selection of Fresh Seasonal Vegetables | Chef’s Selection of Fresh Seasonal Vegetables | Hearth Baked Rolls and Butter ASTRO International Sessions at a

Hearth Baked Rolls and Butter SWEETS Glance ASTRO’s International Education Subcommittee (IES) members have compiled a series SWEETS Carrot Cake and Chocolate Bundt Cake of outstanding educational offerings again for the 2017 Annual Meeting in San Diego. Gourmet Assortment of Fresh Yesterday, the international program kicked off with a Latin American Refresher Course that focused on updating radiation therapy management for common malignancies Baked Cookies and Brownies DRINKS seen in Latin America. The course was presented in Spanish. DRINKS Self Service Beverage Station International attendees, be sure to mark these offerings on your Annual Meeting schedule. Self Service Beverage Station Freshly Brewed Iced Tea and Lemonade Date and time Session Location Freshly Brewed Iced Tea and Sunday, September 24 International Welcome Breakfast 6A Lemonade 6:45 a.m. – 8:00 a.m. Sunday, September 24 ASTRO/ESTRO: Cutting Edge Combined 2 1:15 p.m. – 2:45 p.m. Modality Therapies (Focus on NSCLC) = Vegetarian and Vegan | = Gluten Free Sunday, September 24 Implementation of Prospective Multidis- 31 A/B/C 4:45 p.m. – 6:15 p.m. ciplinary Tumor Board to Optimize Each Individual Patient’s Care (in Chinese) Monday, September 25 Global Perspectives on Challenging Cases 3 7:45 a.m. – 9:00 a.m. in Radiation Oncology: Snapshot of Breast, Lung and Cervix Cancer from Your Local Clinic to Site-specific Thought Leaders Monday, September 25 Managing Acute and Late Side Effects in 11 A/B 10:45 a.m. – 12:15 p.m. Resources Constrained Environment Monday, September 25 Global Collaboration in Clinical Trials: Op- 7 A/B 4:15 p.m. – 5:45 p.m. portunities and Challenges

6 ASTRO DAILY NEWS | Sunday/Monday

PART 1 Gearing Up for QOPI e sat down with ASTRO staff members to better understand the new Quality Oncology Prac- ods. Each set-up is specific and therefore requires a tice Initiative (QOPI)® Reporting Registry. We asked Ksenija Kapetanovic and Randi Kudner, unique set-up period. Wquality improvement managers at ASTRO, to provide us with the information that ASTRO members should know about this new quality reporting registry. Does a practice have to hook up their EHR to use the QCDR? You mentioned that the QCDR will help with MIPS. RK: No. For practices who don’t have the IT staff to sup- Just to back up a little, what do physicians need to port the EHR connection, the QOPI Reporting Registry know about MIPS for 2017? offers a web-interface tool (WIT). Practices who use this KK: In 2017, eligible clinicians are required to partici- can meet the minimum MIPS reporting requirements pate in MIPS to avoid a negative 4 percent payment ad- of one measure for one Medicare Part B patient to avoid justment in 2019. Eligibility information is available on the penalty. Practices do have the opportunity, however, the QPP CMS website based on the physician’s National to report on more than the minimum requirements via Provider Identifier (NPI) number. Data for multiple the WIT, as well. performance categories, including Quality, Improve- ment Activities and Advancing Care Information, can be It sounds like there are many choices about how to collected and submitted to CMS using different mecha- participate in MIPS. Does ASTRO have any sugges- nisms, one of which is a QCDR. The QCDR provides the tions about what to do? ability to report on all MIPS performance categories; KK: In 2017, ASTRO recommends that practices report on however, practices have the option to do the minimum at least four measures to become accustomed to the MIPS 2017 participation or “test pace” to avoid the penalty. program, ensure that the CMS requirements are met and The test pace requires only one Quality measure or increase the likelihood of a positive payment adjustment. one Improvement Activity measure. Two of ASTRO’s ASTRO has created many educational resources to help quality programs, RO-ILS and APEx®, can meet the practices prepare for MIPS, including the ASTRO MIPS Improvement Activities performance category and be website I mentioned before, the MIPS Toolkits and a attested via QOPI Reporting Registry. For more infor- recently held MIPS Open Forum where physicians were Ksenija Kapetanovic and Randi Kudner are ASTRO’s quality mation on MIPS and these programs, be sure to check able to hear directly from radiation oncology practices improvement managers. out www.astro.org/mips or you can visit us in Room 9 who have developed a plan for 2017. You can access all Good afternoon, thank you for speaking with us during our office hours. (See sidebar for details.) of these resources on our website at www.astro.org/mips. today. Let’s start with the basics. What is the QOPI Ultimately, a practice’s decisions about a MIPS plan will Reporting Registry? be unique, based on business goals, available technology Ksenija Kapetanovic (KK): QOPI Reporting Registry and staffing. No matter what a practice decides to do, we is a Qualified Clinical Data Registry (QCDR). This suggest that they take time to truly understand the MIPS means that it is a Centers for Medicare and Medicaid “ ASTRO’s vision is for program so that an educated decision can be made. Services (CMS)-approved entity that collects clinical radiation oncology to be data for improvement in the quality of care provided Check back in Tuesday’s edition of the ASTRO Daily News to patients. A QCDR also serves as a collection and the recognized leader in for part two of our Q&A with ASTRO staff experts as they submission mechanism for the CMS’s Merit-Based quality, innovation and provide more details on how and why to use the QOPI Incentive Payment System (MIPS) program. The QCDR Reporting Registry ● provides a way to continuously aggregate data and value in multidisciplinary calculate performance on quality measures. Constant cancer care.” performance measurement can help practices monitor trends, compare results to benchmarks and identify APEx, MIPS and RO-ILS Office gaps for improvement while satisfying annual CMS Hours requirements. ASTRO is partnering with the American Do you have questions about ASTRO’s quality Society for Clinical Oncology (ASCO) to provide the A QCDR sounds like a powerful reporting tool, but programs, APEx and RO-ILS, or the new Medicare Merit-based Incentive Payment System (MIPS)? QOPI Reporting Registry. FIGmd provides the technol- you said it doesn’t add any burden to practices. How ASTRO staff are available for one-on-one support ogy platform used by the QOPI Reporting Registry as can that be? How does the QCDR work? or team meetings. Whether you are just beginning well as several other QCDRs. RK: The QOPI Reporting Registry connects directly to or currently working on implementing a plan, they the practice’s EHR, and data relevant to the quality are there to help. For individualized APEx assis- Why is ASTRO providing this resource to the mem- measures are extracted and transmitted in real time tance, please email [email protected] to bership? directly into QOPI Reporting Registry. Practices can ac- schedule an appointment. However, inquiries are Randi Kudner (RK): The ASTRO Board is committed to cess the QCDR portal to review the data on a dashboard welcome for all programs. providing resources for its members to facilitate quality and have access to monthly reports. Physicians can also Location: improvement for radiation oncology and meet CMS re- run queries on their patient population to benchmark Room 9, Convention Center quirements. With the increasing adoption of electronic practice performance and uncover potential areas for Hours of operation: health records (EHRs) and other advances in technol- quality improvement. Sunday, September 24 ogy, physicians can perform internal data analysis to 2:30 p.m. – 4:00 p.m. inform better clinical decision-making. ASTRO’s vision Will the QCDR work with any EHR? Monday, September 25 is for radiation oncology to be the recognized leader KK: The registry platform operates regardless of 10:00 a.m. – 11:00 a.m. in quality, innovation and value in multidisciplinary the EHR. Currently, the QOPI QCDR has been tested 2:30 p.m. – 3:30 p.m. cancer care. Partnering with ASCO allows us to work with ARIA® and MOSAIQ® radiation oncology EHRs. Tuesday, September 26: together to strategically implement tools to drive quality FIGmd and local practice information technology 10:30 a.m. – 11:30 a.m. improvement without adding burden to practices. staff will work together to tailor the data extraction 2:00 p.m. – 3:00 p.m. formula to accommodate unique data collection meth-

7 ASTRO DAILY NEWS | Sunday/Monday

Presidential Symposium considers the big issues facing radiation oncology By Leah Kerkman Fogarty, ASTRO Communications Manager

t’s a can’t-miss event—on Sunday, September 24 in Najeeb Mohideen, MD, FASTRO, Stephen T. Lutz, MD, FASTRO, Ballroom 20, thousands of the greatest minds in the Department of Radiation Department of Radiation Oncol- Ifield of radiation oncology will gather to consider Oncology, Northwest Community ogy, Eastern Woods Radiation the state of the specialty. According to ASTRO Pres- Hospital, in Arlington Heights, Oncology, in Findlay, Ohio ident Brian D. Kavanagh, MD, MPH, FASTRO, “this Illinois meeting’s Presidential Symposium is one-part forward thinking, one-part introspective and one-part focused on what patients really want from us in their time of greatest need.” What are the topics you will be covering in this What are the topics you will be covering in your To delve into these three distinct areas, Dr. Kava- session? session? nagh has tapped three leading radiation oncologists “The Art of Quality” will focus on how quality has been This session, “The Quality of Mercy,” will offer insights to lead the discussions. First, Robert D. Timmerman, measured in medicine and specifically what measuring into patients’ feelings in the final stages of illness and MD, will moderate part one, called “The Scientific quality might mean in radiation oncology. The speakers also some perspectives on how best to address their State of the Art.” In part two, Najeeb Mohideen, MD, will discuss health outcome measures in other special- needs during this sensitive time. I’m hoping to facilitate FASTRO, will moderate the session called “The Art ties, as well as institutional experience and expertise everyone else’s talks. of Quality.” And part three will be moderated by Ste- incorporating radiation oncology-specific quality mea- phen T. Lutz, MD, FASTRO, on “The Quality of Mer - sures into the process of care. How has your background prepared you to cover cy.” Dr. Kavanagh also promises cameo appearances these topics? by a couple of other household names in the field. How has your background prepared you to cover I have been board-certified in Hospice and Pallia- We spoke with each of the Presidential Symposium these topics? tive Medicine since 2001. In the interim, I have pub- session moderators to get a sneak peek at the topics I have participated in and led health policy and payment lished more than 100 peer-reviewed manuscripts and that will be covered in today’s symposium. reform efforts in radiation oncology. I served on the book chapters focusing on palliative oncology. I also ASTRO Board of Directors as Chair of the Health Policy founded the Society for Palliative Radiation Oncology, Robert Timmerman, MD, Council, and for many years I was ASTRO’s representa- aka SPRO. Mostly, my background as chief resident Professor of Radiation Oncolo- tive to the American Medical Association Relative Value under Brian Kavanagh when he was residency director gy and Neurosurgery, University Update Committee, usually just called the RUC. at the Medical College of Virginia in the 1990s makes of Texas Southwestern Medical Center, in Dallas

“This meeting’s Presidential Symposium is one-part What are the topics you will be covering in this session? forward thinking, one-part introspective and one-part “The Scientific State of the Art” will feature ideas and inno- focused on what patients really want from us in their time vations hoping to change the way we practice radiation oncology. The speakers will provide glimpses at how the field of greatest need.” is moving forward to improve patient care and outcomes.

How has your background prepared you to cover these topics? Working in teams and partnerships, we have ushered Why are these issues relevant in the current health me uniquely qualified to help him keep the sessions on some of the newer technologies into the clinic and, care climate? course . importantly, showed their value via formal testing and Reforming our health care delivery system to improve published outcomes. the quality and value of care is essential to address Why are these issues relevant in our current health escalating costs and ensure that patients have access to care climate? Why are these issues relevant in our current health high-quality care at the right time, in the right setting. Radiation oncologists are responsible to keep up with care climate? Identifying the appropriate measures by learning from rapidly evolving technologies while simultaneously Technological innovation for its own sake will no longer other specialties and from leading institutions on their providing individualized, personal care. While radiation get a pass from pragmatic decision-makers including experience in this area will be invaluable. therapy provides excellent symptom relief for end-of- patients, patient advocacy groups, payers and health life cancer patients, its monetary costs may need to be policy professionals. We must show the value and bene- What do you feel the biggest takeaways will be from assessed in this patient group. fits relative to costs. this session? Defining quality is a work-in-progress for physicians What do you feel the biggest takeaways will be from What do you feel the biggest takeaways will be from across the entire house of medicine, and our field is your part of the symposium? this session? no exception. I hope that the session suggests at least Radiation oncology: All the technology, all the humanity. ● For those that feel that change is scary, this section will a few helpful benchmarks to assess what happens in be somewhat frightening. But the big take-home is that everyone’s practice, and maybe there will be small the field of radiation oncology has only scratched the improvements in care here and there as a result. I hope Stay up to surface of its potential. We have so much to contribute the discussion sparks new thinking and interest on how date on the #ASTRO17 to our patients and colleagues, both independently and we can create a value-based proposition grounded on Meeting! in combinations of thoughtful therapies. quality for our patients and payers. 8 ASTRO DAILY NEWS | Sunday/Monday

New this Year: Poster Viewing Q&A Sessions STREET TALK

o highlight the more than 1,800 paper posters on display, the Poster What new feature TViewing Q&A Sessions have been are you most excited added as a new feature to the ASTRO Annual Meeting. about at #ASTRO17? In ninety-minute time blocks on Sunday, Monday and Tuesday, authors I’m excited for the new will present their abstracts and answer Science Highlights Sessions. questions. One to five disease sites will be As“ Chair of ASTRO’s Scientific presented at a time, to give all authors the Committee, I realize chance to present, and there will be ample there’s simply no way to time for discussion. All sessions will take attend every ASTRO session place in the Poster Hall. See the Schedule you might be interested in, so the Science Highlights are a at a Glance on pages 3 and 4 for the Poster View - tember 25, from 5:30 p.m. to 6:45 p.m. in Hall A-B1 great way to get a snapshot of ing Q&A Sessions times. on the ground floor provides another great opportu- the cutting-edge research that The poster reception on Monday evening, Sep- nity to view posters and hear from the authors. is coming out of our specialty.” —Benjamin Movsas, MD, FASTRO, Chair, Radiation Oncology, Henry Ford Hospital, Detroit

ASTRO UNRESTRICTED EDUCATIONAL ASTROGRANT UNRESTRICTED SUPPORTERS This year, we’re incorporating more opportunities for the1,800-plus“ poster present- EDUCATIONAL GRANT SUPPORTERS ers to share their work with AMGEN attendees. We created Poster Viewing Session Q&A Sessions, held Sunday, Monday and Tues- Amgen 6:15 p.m. – 6:45 p.m. Dinner and Registration ASTELLAS day in the Poster Hall, where Astellas 6:45attendees p.m. – can8:15 visit p.m. posters and Symposium ASTRAZENECA speak directly with the authors NEW OPPORTUNITIESabout their research. TO IMPROVE We believe OUTCOMES IN LOCALLY ADVANCED, AstraZenecaGENOMIC UNRESECTABLEthis will LUNG be a CANCER: great opportunity INTEGRATING IMMUNOTHERAPY INTO A to networkMULTIMODAL and learn for TREATMENT both APPROACH presenters and attendees.” Genomic Venue Location: Hilton San Diego Bayfront, Sapphire AB LILLY —Cristin Watson, Assistant Director, DinnerEducation, will ASTRObe provided. MERCKLilly NOVOCUREMerck Since ASTRO represents one Novocure of the most technologically PFIZER innovative“ specialties, I am very interested to see the Pfi zer new products and services featured in the Product 2017 ANNUAL MEETING Showcase, located outside of 2017 ANNUAL MEETING the Innovation and Solution PROMOTIONAL SPONSORS Showcase.” PROMOTIONAL SPONSORS —Tim Myers, Senior Director of National Accounts at GES, the management company for ASTRO 2017

I think the ASTRO Connect booths, and especially the Meet“ the Expert opportunities there, will be a popular new HOLOGIC VISION RT, LTD feature with attendees. As each of these hubs have their own subspecialty focus, ALLIANCE ONCOLOGY MIRADA MEDICAL they will be a great spot for attendees with similar SUN NUCLEAR CORPORATION VERTUAL, LTD interests to connect and network.” —Michele Donohue, Director, Meetings, ASTRO 50 ASTRO’S 59TH ANNUAL MEETING | EXHIBITOR DIRECTORY 9

2017 - Annual Meeting - Exhibitor Listing (Tab 4 - IET and ISS).indd 50 8/18/2017 10:46:23 AM B:21.75” T:21.5” S:19.5”

For mCRPC Introduce Xofigo® at the first sign of progression on hormonal therapy * patients with symptomatic bone metastases

SIGNIFICANTLY EXTEND OVERALL SURVIVAL OS ,a

MEDIANMEDIAN OS OS WITH IN AN OR EXPLORATORY WITHOUT CONCOMITANT ANALYSIS ,b USE OF ABIRATERONE a

100 HR=. % CI: ..

80 14.9 MONTHS Planned for Xofigo + BSOC 70 course (n=64) of Xofigo (% CI: ..) 60 % treatment 30 50 is 6 doses reduction in the risk of 40 death vs placebo 11.3 , 30 MONTHS (HR=. for placebo + BSOC 20 (n=307) Probability of survival (%) survival of Probability (95% CI: 0.4-2.8) 10

0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 Time (months)

Xogo 614 578 504 369 277 178 105 60 41 18 7 1 0 0 Placebo 307 288 228 157 104 67 39 24 14 7 4 2 1 0

aIn the prespeci ed interim analysis. B:14.25” T:13.75” bAn exploratory updated OS analysis was performed before patient crossover, incorporating an additional £ events, resulting in ndings S:12.75” consistent with the interim analysis. • Evaluated in a double-blind, randomized, placebo-controlled phase clinical trial of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases *In ALSYMPCA, best standard of care (BSOC) was de ned as antihormonal agents, local external beam radiation therapy (EBRT), • Prespecified interim analysis: median OS was . months for Xofigo ( % Conf idence interval ketoconazole, and treatment with glucocorticoids.2 [CI]: . .) vs . months for placebo ( % CI: ..) mCRPC=Metastatic Castration-Resistant Prostate Cancer. – P =. ; Hazard ratio [HR]=. (% CI: ..)

XOFIGO® IS INDICATED for the treatment of with myelosuppression were observed in % of Xo go-treated • Concomitant Use With Chemotherapy: Safety and e¡ cacy of peripheral edema (% vs %). Grade and adverse patients compared to .% of patients treated with placebo. concomitant chemotherapy with Xo go have not been established. events were reported in % of Xo go-treated patients patients with castration-resistant prostate cancer The incidence of infection-related deaths (%), serious Outside of a clinical trial, concomitant use of Xo go in patients on and % of placebo-treated patients. The most common (CRPC), symptomatic bone metastases and no infections (%), and febrile neutropenia (<%) was similar for chemotherapy is not recommended due to the potential for additive hematologic laboratory abnormalities in the Xo go known visceral metastatic disease. patients treated with Xo go and placebo. Myelosuppression— myelosuppression. If chemotherapy, other systemic radioisotopes, arm (≥%) vs the placebo arm, respectively, were notably thrombocytopenia, neutropenia, pancytopenia, and or hemibody external radiotherapy are administered during the anemia (% vs 88%), lymphocytopenia (% vs %), Important Safety Information leukopenia—has been reported in patients treated with Xo go. treatment period, Xo go should be discontinued leukopenia (% vs %), thrombocytopenia (% vs %), • Contraindications: Xo go is contraindicated in women who Monitor patients with evidence of compromised bone marrow • Administration and Radiation Protection: Xo go should be and neutropenia (% vs %) are or may become pregnant. Xo go can cause fetal harm reserve closely and provide supportive care measures when received, used, and administered only by authorized persons References: . X o g o® (radium Ra ££¦ dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; when administered to a pregnant woman clinically indicated. Discontinue Xo go in patients who in designated clinical settings. The administration of Xo go is March £. . Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA • Bone Marrow Suppression: In the randomized trial, % of experience life-threatening complications despite supportive associated with potential risks to other persons from radiation or Investigators. Alpha emitter radium-££¦ and survival in metastatic patients in the Xo go arm experienced bone marrow failure care for bone marrow failure contamination from spills of bodily fluids such as urine, feces, or prostate cancer. N Engl J Med. £¦;¦®¯¦°:£¦±££¦. or ongoing pancytopenia, compared to no patients treated • Hematological Evaluation: Monitor blood counts at baseline vomit. Therefore, radiation protection precautions must be taken Please see following pages for brief summary of with placebo. There were two deaths due to bone marrow and prior to every dose of Xo go. Prior to rst administering in accordance with national and local regulations full Prescribing Information. failure. For of patients treated with Xo go bone marrow Xo go, the absolute neutrophil count (ANC) should be • Adverse Reactions: The most common adverse reactions (≥%) failure was ongoing at the time of death. Among the patients ≥. × /L, the platelet count ≥ × /L, and hemoglobin in the Xo go arm vs the placebo arm, respectively, were nausea who experienced bone marrow failure, % required blood ≥ g/dL. Prior to subsequent administrations, the ANC should % vs %), diarrhea % vs %), vomiting (% vs %), and transfusions. Four percent %) of patients in the Xo go be ≥ × /L and the platelet count ≥ × /L. Discontinue arm and % in the placebo arm permanently discontinued Xo go if hematologic values do not recover within 6 to 8 weeks radium Ra 223 dichloride therapy due to bone marrow suppression. In the randomized after the last administration despite receiving supportive care INJECTION © Bayer. All rights reserved. trial, deaths related to vascular hemorrhage in association BAYER, the Bayer Cross, and Xo go are registered trademarks of Bayer. PP--US- / Printed in USA Learn more about Xo go at hcp.xo go-us.com

10762269_HCP_JA_King_Rsz_M3.indd 1 9/18/17 12:57 PM F:10.75” F:10.75”

PREPARED BY AREA Releasing as: PDF-Xa Production: Laurette Mercer x2664 Job #: AD: Colors: 4C Client: BAYER AE: Morgan Carey 2674 Product: XOGFIGO Bleed: 21.75"w x 14.25"h Producer: Pearle Wong x Client Code: PP--US- Trim: 10.75"w x 13.75"h Digital Artist: CL, CL, NJ Date: September 18, 2017 12:57 PM Live: 9.75"w x 12.75"h Add’l Size Info: Proof: M Fonts: Meta Pro M Spellcheck: CC FR Spellcheck: Path: Area23:Bayer:Xo go:10762269:10762269_HCP_JA_King_Rsz:10762269_HCP_JA_King_Rsz_M3 4C HCP Journal Ad King Resize B:21.75” T:21.5” S:19.5”

For mCRPC Introduce Xofigo® at the first sign of progression on hormonal therapy * patients with symptomatic bone metastases

SIGNIFICANTLY EXTEND OVERALL SURVIVAL OS ,a

MEDIANMEDIAN OS OS WITH IN AN OR EXPLORATORY WITHOUT CONCOMITANT ANALYSIS ,b USE OF ABIRATERONE a

100 HR=. % CI: ..

0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 Time (months)

Xogo 614 578 504 369 277 178 105 60 41 18 7 1 0 0 Placebo 307 288 228 157 104 67 39 24 14 7 4 2 1 0

10762269_HCP_JA_King_Rsz_M3.indd 1 9/18/17 12:57 PM F:10.75” F:10.75”

XOFIGO (radium Ra 223 dichloride) Injection, for intravenous use Hematologic evaluation of patients must be performed at baseline and prior Fluid Status 8.8 Males of Reproductive Potential Initial U.S. Approval: 2013 to every dose of Xofigo. Before the first administration of Xofigo, the absolute Dehydration occurred in 3% of patients on Xofigo and 1% of patients on Contraception neutrophil count (ANC) should be ≥ 1.5 x 109/L, the platelet count ≥ 100 x 109/L placebo. Xofigo increases adverse reactions such as diarrhea, nausea, and Because of potential effects on spermatogenesis associated with radiation, BRIEF SUMMARY oF pREScRIBIng InFoRMAtIon and hemoglobin ≥ 10 g/dL. Before subsequent administrations of Xofigo, the vomiting which may result in dehydration. Monitor patients’ oral intake and fluid advise men who are sexually active to use condoms and their female partners of conSULt pAcKAgE InSERt FoR FULL pREScRIBIng InFoRMAtIon ANC should be ≥ 1 x 109/L and the platelet count ≥ 50 x 109/L. If there is no status carefully and promptly treat patients who display signs or symptoms of reproductive potential to use a highly effective contraceptive method during and recovery to these values within 6 to 8 weeks after the last administration of dehydration or hypovolemia. for 6 months after completing treatment with Xofigo. 1 INDICATIONS AND USAGE Xofigo, despite receiving supportive care, further treatment with Xofigo should Xofigo® is indicated for the treatment of patients with castration-resistant be discontinued. Patients with evidence of compromised bone marrow reserve Injection Site Reactions Infertility prostate cancer, symptomatic bone metastases and no known visceral metastatic should be monitored closely and provided with supportive care measures Erythema, pain, and edema at the injection site were reported in 1% of patients There are no data on the effects of Xofigo on human fertility. There is a potential disease. when clinically indicated. Discontinue Xofigo in patients who experience life- on Xofigo. risk that radiation by Xofigo could impair human fertility [see Nonclinical 2 DOSAGE AND ADMINISTRATION threatening complications despite supportive care for bone marrow failure. Secondary Malignant Neoplasms Toxicology (13.1)]. 2.3 Instructions for Use/Handling The safety and efficacy of concomitant chemotherapy with Xofigo have not Xofigo contributes to a patient’s overall long-term cumulative radiation exposure. been established. Outside of a clinical trial, concomitant use with chemotherapy 10 OVERDOSAGE General warning Long-term cumulative radiation exposure may be associated with an increased There have been no reports of inadvertent overdosing of Xofigo during clinical is not recommended due to the potential for additive myelosuppression. risk of cancer and hereditary defects. Due to its mechanism of action and Xofigo (an alpha particle-emitting pharmaceutical) should be received, used and If chemotherapy, other systemic radioisotopes or hemibody external studies. administered only by authorized persons in designated clinical settings. The neoplastic changes, including osteosarcomas, in rats following administration radiotherapy are administered during the treatment period, Xofigo should be of radium-223 dichloride, Xofigo may increase the risk of osteosarcoma or There is no specific antidote. In the event of an inadvertent overdose of receipt, storage, use, transfer and disposal Xofigo are subject to the regulations discontinued. Xofigo, utilize general supportive measures, including monitoring for potential and/or appropriate licenses of the competent official organization. other secondary malignant neoplasms [see Nonclinical Toxicology (13.1)]. However, the overall incidence of new malignancies in the randomized trial was hematological and gastrointestinal toxicity, and consider using medical Xofigo should be handled by the user in a manner which satisfies both radiation 6 ADVERSE REACTIONS countermeasures such as aluminum hydroxide, barium sulfate, calcium The following serious adverse reactions are discussed in greater detail in another lower on the Xofigo arm compared to placebo (<1% vs. 2%; respectively), but safety and pharmaceutical quality requirements. Appropriate aseptic precautions the expected latency period for the development of secondary malignancies carbonate, calcium gluconate, calcium phosphate, or sodium alginate. should be taken. section of the label: Single Xofigo doses up to 274 kBq (7.41 microcurie) per kg body weight were • Bone Marrow Suppression [see Warnings and Precautions (5.1)] exceeds the duration of follow up for patients on the trial. Radiation protection evaluated in a phase 1 clinical trial and no dose-limiting toxicities were observed. 6.1 Clinical Trials Experience Subsequent Treatment with Cytotoxic Chemotherapy The administration of Xofigo is associated with potential risks to other persons 13 NONCLINICAL TOXICOLOGY (e.g., medical staff, caregivers and patient’s household members) from radiation Because clinical trials are conducted under widely varying conditions, adverse In the randomized clinical trial, 16% patients in the Xofigo group and 18% or contamination from spills of bodily fluids such as urine, feces, or vomit. reaction rates observed in the clinical trials of a drug cannot be directly patients in the placebo group received cytotoxic chemotherapy after completion 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Therefore, radiation protection precautions must be taken in accordance with compared to rates in the clinical trials of another drug and may not reflect the of study treatments. Adequate safety monitoring and laboratory testing was not Animal studies have not been conducted to evaluate the carcinogenic potential national and local regulations. rates observed in practice. performed to assess how patients treated with Xofigo will tolerate subsequent of radium-223 dichloride. However, in repeat-dose toxicity studies in rats, cytotoxic chemotherapy. osteosarcomas, a known effect of bone-seeking radionuclides, were observed For drug handling In the randomized clinical trial in patients with metastatic castration-resistant prostate cancer with bone metastases, 600 patients received intravenous 7 DRUG INTERACTIONS at clinically relevant doses 7 to 12 months after the start of treatment. The Follow the normal working procedures for the handling of radiopharmaceuticals presence of other neoplastic changes, including lymphoma and mammary gland and use universal precautions for handling and administration such as gloves and injections of 55 kBq/kg (1.49 microcurie/kg) of Xofigo and best standard of No formal clinical drug interaction studies have been performed. care and 301 patients received placebo and best standard of care once every 4 carcinoma, was also reported in 12- to 15-month repeat-dose toxicity studies barrier gowns when handling blood and bodily fluids to avoid contamination. In Subgroup analyses indicated that the concurrent use of bisphosphonates or in rats. case of contact with skin or eyes, the affected area should be flushed immediately weeks for up to 6 injections. Prior to randomization, 58% and 57% of patients calcium channel blockers did not affect the safety and efficacy of Xofigo in the Genetic toxicology studies have not been conducted with radium-223 dichloride. with water. In the event of spillage of Xofigo, the local radiation safety officer had received docetaxel in the Xofigo and placebo arms, respectively. The randomized clinical trial. median duration of treatment was 20 weeks (6 cycles) for Xofigo and 18 weeks However, the mechanism of action of radium-223 dichloride involves induction of should be contacted immediately to initiate the necessary measurements and double-strand DNA breaks, which is a known effect of radiation. required procedures to decontaminate the area. A complexing agent such as 0.01 (5 cycles) for placebo. 8 USE IN SPECIFIC POPULATIONS M ethylene-diamine-tetraacetic acid (EDTA) solution is recommended to remove The most common adverse reactions (≥ 10%) in patients receiving Xofigo 8.1 Pregnancy Category X [see Contraindications (4)] Animal studies have not been conducted to evaluate the effects of radium-223 contamination. were nausea, diarrhea, vomiting, and peripheral edema (Table 3). Grade 3 and Xofigo can cause fetal harm when administered to a pregnant woman based on dichloride on male or female fertility or reproductive function. Xofigo may impair 4 adverse events were reported among 57% of Xofigo-treated patients and its mechanism of action. While there are no human or animal data on the use of fertility and reproductive function in humans based on its mechanism of action. For patient care 63% of placebo-treated patients. The most common hematologic laboratory Xofigo in pregnancy and Xofigo is not indicated for use in women, maternal use 17 PATIENT COUNSELING INFORMATION Whenever possible, patients should use a toilet and the toilet should be flushed abnormalities in Xofigo-treated patients (≥ 10%) were anemia, lymphocytopenia, of a radioactive therapeutic agent could affect development of a fetus. Xofigo is several times after each use. When handling bodily fluids, simply wearing gloves leukopenia, thrombocytopenia, and neutropenia (Table 4). contraindicated in women who are or may become pregnant while receiving the Advise patients: and hand washing will protect caregivers. Clothing soiled with Xofigo or patient Treatment discontinuations due to adverse events occurred in 17% of patients drug. If this drug is used during pregnancy, or if the patient becomes pregnant • To be compliant with blood cell count monitoring appointments while fecal matter or urine should be washed promptly and separately from other clothing. who received Xofigo and 21% of patients who received placebo. The most while taking this drug, apprise the patient of the potential hazard to the fetus and receiving Xofigo. Explain the importance of routine blood cell counts. Instruct B:14.25” T:13.75” Radium-223 is primarily an alpha emitter, with a 95.3% fraction of energy emitted common hematologic laboratory abnormalities leading to discontinuation for the potential risk for pregnancy loss. Advise females of reproductive potential to patients to report signs of bleeding or infections. S:12.75” as alpha-particles. The fraction emitted as beta-particles is 3.6%, and the fraction Xofigo were anemia (2%) and thrombocytopenia (2%). avoid becoming pregnant during treatment with Xofigo. • To stay well hydrated and to monitor oral intake, fluid status, and urine emitted as gamma-radiation is 1.1%. The external radiation exposure associated Table 3 shows adverse reactions occurring in ≥ 2% of patients and for which the 8.3 Nursing Mothers output while being treated with Xofigo. Instruct patients to report signs of with handling of patient doses is expected to be low, because the typical treatment incidence for Xofigo exceeds the incidence for placebo. dehydration, hypovolemia, urinary retention, or renal failure / insufficiency. activity will be below 8,000 kBq (216 microcurie). In keeping with the As Low As Xofigo is not indicated for use in women. It is not known whether radium-223 Table 3: Adverse Reactions in the Randomized Trial dichloride is excreted in human milk. Because many drugs are excreted in • There are no restrictions regarding contact with other people after receiving Reasonably Achievable (ALARA) principle for minimization of radiation exposure, Xofigo. Follow good hygiene practices while receiving Xofigo and for at least it is recommended to minimize the time spent in radiation areas, to maximize the System/Organ Class Xofigo (n=600) Placebo (n=301) human milk, and because of potential for serious adverse reactions in nursing infants from Xofigo, a decision should be made whether to discontinue 1 week after the last injection in order to minimize radiation exposure from distance to radiation sources, and to use adequate shielding. Any unused product Preferred Term Grades 1-4 Grades 3-4 Grades 1-4 Grades 3-4 bodily fluids to household members and caregivers. Whenever possible, or materials used in connection with the preparation or administration are to be nursing, or discontinue the drug taking into account the importance of the % % % % drug to the mother. patients should use a toilet and the toilet should be flushed several times treated as radioactive waste and should be disposed of in accordance with local after each use. Clothing soiled with patient fecal matter or urine should be regulations. Blood and lymphatic system disorders 8.4 Pediatric Use washed promptly and separately from other clothing. Caregivers should use The gamma radiation associated with the decay of radium-223 and its daughters Pancytopenia 2 1 0 0 The safety and efficacy of Xofigo in pediatric patients have not been established. universal precautions for patient care such as gloves and barrier gowns when allows for the radioactivity measurement of Xofigo and the detection of Gastrointestinal disorders In single- and repeat-dose toxicity studies in rats, findings in the bones (depletion handling bodily fluids to avoid contamination. When handling bodily fluids, contamination with standard instruments. of osteocytes, osteoblasts, osteoclasts, fibro-osseous lesions, disruption/ wearing gloves and hand washing will protect caregivers. Nausea 36 2 35 2 4 CONTRAINDICATIONS disorganization of the physis/growth line) and teeth (missing, irregular growth, • Who are sexually active to use condoms and their female partners of Xofigo is contraindicated in pregnancy. Diarrhea 25 2 15 2 fibro-osseous lesions in bone socket) correlated with a reduction of osteogenesis reproductive potential to use a highly effective method of birth control during Vomiting 19 2 14 2 that occurred at clinically relevant doses beginning in the range of 22 – 88 kBq treatment and for 6 months following completion of Xofigo treatment. Xofigo can cause fetal harm when administered to a pregnant woman based (0.59 - 2.38 microcurie) per kg body weight. on its mechanism of action. Xofigo is not indicated for use in women. Xofigo General disorders and administration site conditions is contraindicated in women who are or may become pregnant. If this drug is 8.5 Geriatric Use used during pregnancy, or if the patient becomes pregnant while taking this Peripheral edema 13 2 10 1 Of the 600 patients treated with Xofigo in the randomized trial, 75% were 65 drug, apprise the patient of the potential hazard to the fetus [see Use in Specific Renal and urinary disorders years of age and over and while 33% were 75 years of age and over. No dosage Populations (8.1)]. Renal failure and impairment 3 1 1 1 adjustment is considered necessary in elderly patients. No overall differences in safety or effectiveness were observed between these subjects and younger 5 WARNINGS AND PRECAUTIONS Laboratory Abnormalities subjects, and other reported clinical experience has not identified differences in 5.1 Bone Marrow Suppression Table 4 shows hematologic laboratory abnormalities occurring in > 10% of responses between the elderly and younger patients, but greater sensitivity of In the randomized trial, 2% of patients on the Xofigo arm experienced bone patients and for which the incidence for Xofigo exceeds the incidence for placebo. some older individuals cannot be ruled out. Manufactured for: marrow failure or ongoing pancytopenia compared to no patients treated with placebo. There were two deaths due to bone marrow failure and for 7 of 13 Table 4: Hematologic Laboratory Abnormalities 8.6 Patients with Hepatic Impairment No dedicated hepatic impairment trial for Xofigo has been conducted. Since patients treated with Xofigo, bone marrow failure was ongoing at the time of Hematologic Xofigo (n=600) Placebo (n=301) death. Among the 13 patients who experienced bone marrow failure, 54% radium-223 is neither metabolized by the liver nor eliminated via the bile, Laboratory required blood transfusions. Four percent (4%) of patients on the Xofigo arm and Grades 1-4 Grades 3-4 Grades 1-4 Grades 3-4 hepatic impairment is unlikely to affect the pharmacokinetics of radium-223 Bayer HealthCare Pharmaceuticals Inc. Abnormalities dichloride [see Clinical Pharmacology (12.3)]. Based on subgroup analyses in 2% on the placebo arm permanently discontinued therapy due to bone marrow % % % % Whippany, NJ 07981 suppression. Anemia 93 6 88 6 the randomized clinical trial, dose adjustment is not needed in patients with mild hepatic impairment. No dose adjustments can be recommended for patients with Manufactured in Norway In the randomized trial, deaths related to vascular hemorrhage in association Lymphocytopenia 72 20 53 7 with myelosuppression were observed in 1% of Xofigo-treated patients moderate or severe hepatic impairment due to lack of clinical data. Leukopenia 35 3 10 <1 compared to 0.3% of patients treated with placebo. The incidence of infection- 8.7 Patients with Renal Impairment Xofigo is a trademark of Bayer Aktiengesellschaft. related deaths (2%), serious infections (10%), and febrile neutropenia (<1%) Thrombocytopenia 31 3 22 <1 No dedicated renal impairment trial for Xofigo has been conducted. Based on © 2013, Bayer HealthCare Pharmaceuticals Inc. were similar for patients treated with Xofigo and placebo. Myelosuppression; Neutropenia 18 2 5 <1 subgroup analyses in the randomized clinical trial, dose adjustment is not needed notably thrombocytopenia, neutropenia, pancytopenia, and leukopenia; has been in patients with existing mild (creatinine clearance [CrCl] 60 to 89 mL/min) or All rights reserved. reported in patients treated with Xofigo. In the randomized trial, complete blood Laboratory values were obtained at baseline and prior to each 4-week cycle. moderate (CrCl 30 to 59 mL/min) renal impairment. No dose adjustment can be Revised: March 2016 counts (CBCs) were obtained every 4 weeks prior to each dose and the nadir As an adverse reaction, grade 3-4 thrombocytopenia was reported in 6% of recommended for patients with severe renal impairment (CrCl less than 30 mL/ CBCs and times of recovery were not well characterized. In a separate single- patients on Xofigo and in 2% of patients on placebo. Among patients who received min) due to limited data available (n = 2) [see Clinical Pharmacology (12.3)]. 6708401BS dose phase 1 study of Xofigo, neutrophil and platelet count nadirs occurred 2 Xofigo, the laboratory abnormality grade 3-4 thrombocytopenia occurred in 1% of to 3 weeks after Xofigo administration at doses that were up to 1 to 5 times the docetaxel naïve patients and in 4% of patients who had received prior docetaxel. recommended dose, and most patients recovered approximately 6 to 8 weeks Grade 3-4 neutropenia occurred in 1% of docetaxel naïve patients and in 3% of after administration [see Adverse Reactions (6)]. patients who have received prior docetaxel.

10762269_HCP_JA_King_Rsz_M3.indd 2 9/18/17 12:57 PM F:10.75” F:10.75” B:21.75” T:21.5” S:19.5”

10762269_HCP_JA_King_Rsz_M3.indd 2 9/18/17 12:57 PM F:10.75” F:10.75” ASTRO DAILY NEWS | Sunday/Monday

Increasing the profile of radiation oncology ASTRO’s new strategic plan and vision

By David C. Beyer, MD, FASTRO, Chair, ASTRO Board of Directors

t last year’s Annual Meeting in Boston, I outlined 1. Establish radiation oncology as an equal part- medicine to the fullest extent to benefit their some of my priorities as Chair of the ASTRO ner in cancer field. patients. ABoard of Directors. High on that list was my goal Today, radiation oncology is a vibrant specialty The new plan does not forget that ASTRO must be to work with ASTRO membership and the Board to and an equal partner in cancer care—but we vigilant in its efforts to help craft health policy that develop a new strategic must work to live that every day. This requires supports our ability to succeed—which will result in plan that would guide the that we act as leaders in clinical care and that better outcomes for our patients. This will include Society as we navigate both patients and referring physicians know we facilitating our ability to participate in government the increasingly turbulent are caring for the whole patient. We must work programs, such as the Merit-based Incentive Pay- waters of the health care to elevate the field by increasing the positive ment System (MIPS), and creating and implement- landscape in the United public perception of radiation oncology as an in- ing a new Alternative Payment Model (APM). Our States. novative specialty, generating impactful science, advocacy efforts also require vigilance to protect Over the past year, providing advice and input to physician peers access to radiation therapy for all patients. we have gathered input on oncology issues and reflecting the diversity from the membership, of the patients we serve. 4. Consistently deliver the highest quality and ASTRO staff and the value care to cancer patients. Board of Directors to aid 2. Retain and foster the intellectual research At the end of the day, it all comes back to patient in the development of our talent currently entering the field of radiation care. This strategic plan recognizes that it is critically new strategic plan. While oncology. important that we deliver high-quality and high-val- it may seem intuitive, as a result of these conversa- ASTRO’s Science Council has created a research ue care to all the patients we serve. ASTRO already tions, we have articulated ASTRO’s core purpose: to agenda of big and small questions that need an- supports this goal with programs like the ASTRO advance the field of radiation oncology.But in order swers to solidify our place on the cancer care team Accreditation Program for Excellence (APEx®) and to advance the field, we must focus on our vision of of tomorrow. We can help foster research within the RO-ILS: Radiation Oncology Incident Learning what success looks like for ASTRO and its members. our specialty by increasing visibility of the inno- System®. Through this strategic plan, though, we can This leads to the vision that radiation oncology is the vative research already being done by those in increase participation in these programs. recognized leader in quality, innovation and value our field, increasing our collaborations with those in multidisciplinary cancer care. outside of our specialty and identifying how to The ASTRO strategic plan is one we can live by. As part of the new strategic plan, we have created best train and encourage early career researchers. Success in one area will support the success in other four goals—steps for ASTRO and its members to take areas. Please help us achieve the goals set forth in over the coming years to help achieve this vision. 3. Shape the health policy environment to sup- this plan. I welcome your ideas and comments at port radiation oncologists’ ability to practice [email protected].

The Product Showcase debuts at #ASTRO17

Located outside Hall F, the Product Showcase highlights products and services in the Company Name: Novocure Company Name: Siemens Healthineers radiation oncology field. Attendees can search for and learn about any of the products Booth Number: 1825 Booth Number: 705 featured in the Product Showcase by viewing photos, videos and detailed information Product Name: Optune® Product Name: MAGNETOM RT Pro about each product. Turn-by-turn directions are provided to the company’s booth to edition for MAGNETOM Vida help attendees easily find these products once inside the hall. You can also view prod- Company Name: Philips ucts in the ASTRO 2017 Product Showcase via ASTROmobile, the official meeting app, Booth Number: 1835 Company Name: Siemens Healthineers and the Online Conference Planner at www.astro.org/conferenceplanner. Product Name: Pinnacle3 16 Booth Number: 705 Indicates new product Product Name: SOMATOM Confidence® Company Name: Philips RT Pro Company Name: Accuray Incorporated Company Name: Elekta Booth Number: 1835 Booth Number: 1517 Booth Number: 1917 Product Name: RTdrive MR Prostate Company Name: Sun Nuclear Product Name: PreciseArt™ Adaptive Product Name: MOSAIQ® Oncology Corporation Radiation Therapy option Analytics Company Name: Radiological Imaging Booth Number: 1536 Technology, Inc. (RIT) Product Name: SunCHECK™ Integrated Company Name: Augmenix Company Name: Equicare Health Inc. Booth Number: 1631 QA Platform Booth Number: 2917 Booth Number: 2455 Product Name: RITG135 for All Product Name: SpaceOAR® Hydrogel Product Name: Equicare CS ™ (ECS) CyberKnife® Machine QA Company Name: Varian Medical Systems Booth Number: 717 Company Name: Brainlab Company Name: Ion Beam Applications (IBA) Company Name: RaySearch Product Name: Halcyon™ Radiotherapy Booth Number: 1331 Booth Number: 2135 Laboratories AB System Product Name: Brainlab Elements Product Name: Proteus®ONE Booth Number: 1647 Product Name: RayCare Company Name: Bristol-Myers Squibb Company Name: Mirada Medical Stay up to date on the #ASTRO17 Booth Number: 3524 Booth Number: 539 Meeting! Product Name: OPDIVO® (nivolumab) Product Name: Zero-Click Contouring™ 14 ASTRO DAILY NEWS | Sunday/Monday

Network and Learn at ASTRO Connect Areas

ased on attendee feedback, ASTRO is introduc- Tuesday, September 26, 4:15 p.m. – 4:45 p.m. Tuesday, September 26, 4:15 p.m. – 4:45 p.m. ing ASTRO Connect areas located throughout Alphonse Taghian, MD, PhD, FASTRO, Massachusetts Drew Moghanaki, MD, MPH, Hunter Holmes McGuire VA Bthe Innovation and Solution Showcase (formerly General Hospital Medical Center the Exhibit Hall). Each location will have a different focus—breast, gastrointestinal, genitourinary, lung or GASTROINTESTINAL – Booth #3021 LUNG – Booth #3709 physics—and offer attendees a comfortable spot for Sunday, September 24, 2:45 p.m. – 3:15 p.m. Sunday, September 24, 2:45 p.m. – 3:15 p.m. networking with colleagues with similar interests. Bruce Minsky, MD, MB, FASTRO, MD Anderson Cancer Kenneth Rosenzweig, MD, FASTRO, Icahn School of Med- Center icine at Mount Sinai While recharging electronic devices or checking email, visitors may also peruse top posters in each disease Monday, September 25, 10:15 a.m. – 10:45 a.m. Monday, September 25, 3:45 p.m. – 4:15 p.m. site, which will be on display electronically, or speak Lisa Kachnic, MD, FASTRO, Vanderbilt University Medical Percy Lee, MD, University of California, Los Angeles with subject matter experts, who will be available Center during designated times to answer questions and Tuesday, September 26, 4:15 p.m. – 4:45 p.m. discuss science being presented at the meeting. Check Monday, September 25, 3:45 p.m. – 4:15 p.m. Alexander Louie, MD, PhD, MSc, London Health Sciences out the Meet the Expert schedule below for specific Karyn Goodman, MD, MS, University of Colorado Cancer Centre times and locations. Center PHYSICS – Booth #530 MEET THE EXPERT SCHEDULE Tuesday, September 26, 4:15 p.m. – 4:45 p.m. Sunday, September 24, 2:45 p.m. – 3:15 p.m. Theodore Hong, MD, Massachusetts General Hospital Søren Bentzen, DSc, PhD, University of Maryland School BREAST – Booth #405 of Medicine Sunday, September 24, 2:45 p.m. – 3:15 p.m. GENITOURINARY – Booth #3739 Bruce Haffty, MD, FASTRO, Rutgers Cancer Institute of Sunday, September 24, 2:45 p.m. – 3:15 p.m. Monday, September 25, 10:15 a.m. – 10:45 a.m. New Jersey David Beyer, MD, FASTRO, Cancer Center of Northern Indrin Chetty, PhD, MS, Henry Ford Hospital Arizona Monday, September 25, 10:15 a.m. – 10:45 a.m. Monday, September 25, 3:45 p.m. – 4:15 p.m. Julia White, MD, FASTRO, Ohio State University Compre- Monday, September 25, 10:15 a.m. – 10:45 a.m. Martha Matuszak, PhD, University of Michigan hensive Cancer Center Colleen Lawton, MD, FASTRO, Medical College of Wisconsin Tuesday, September 26, 4:15 p.m. – 4:45 p.m. Monday, September 25, 3:45 p.m. – 4:15 p.m. Monday, September 25, 3:45 p.m. – 4:15 p.m. Lei Dong, PhD, University of Pennsylvania Catherine Park, MD, University of California, San Fran- Theodore DeWeese, MD, FASTRO, Johns Hopkins School cisco of Medicine 15 ASTRO DAILY NEWS | Sunday/Monday

The state of the radiation oncologist workforce—and predictions for the future arlier this year, the ASTRO Workforce therapy? Is the workforce located where patients Israel Deaconess Medical Center, will present Subcommittee embarked on a study of the radiation are located? compensation and employment models. Eoncologist workforce. The study is intended to A few highlights from the 2017 ASTRO Workforce examine demographics, economic conditions and 5. Are radiation oncologists finding it necessary to Survey: practice trends that may provide insight into the work in multiple locations to make care accessible demand for radiation oncologists and cancer care in the to patients? • Nearly one-third of respondents who practice in United States. The Subcommittee administered a web- rural areas plan to retire or move to part-time in based survey, phase one of the broader workforce study, 6. Do radiation oncologists tend to stay at their place the next five years, compared with 17 percent of on February 6, 2017, to all domestic Active and Affiliate of employment, or are they transient? What factors urban/suburban practitioners. ASTRO member radiation oncologists. The survey underlie longevity and mobility in the workforce? instrument was largely based on the 2012 workforce • Sixty percent of respondents who searched for survey with additional questions added to probe 7. How is the workload for radiation oncologists a job in the past three years had a difficult time emerging practice patterns and compensation trends. changing, in terms of patient care, administrative finding a position; the major reasons were lack A total of 1,187 surveys were returned, of which duties and other work activities? How is the change of positions in their desired area and lack of 1,174 were retained for analysis for a response rate of 31 in workload being managed? opportunities. Difficulty in finding a position has percent. The respondents represented 729 radiation on- increased compared to 2012. cology practices. Face validity testing comparing work 8. How are radiation oncologists compensated? Have status, gender, race/ethnicity, geographic location and compensation models or levels changed? • Over half of respondents are concerned about a employer type of the 2017 survey respondents against CORPORATEfuture oversupply AMBASSADORS of qualified radiation oncologists. the ASTRO membershipMonday, database September and/or the25, 2012 2017 sur- 9. How has the Affordable Care Act impacted or- vey sample confirmed representativeness of the data. ganizational structures and payment models at • Private/solo practices report the lowest utilization ASTRO PROUDLY RECOGNIZES THE ONGOING COMMITMENT OF OUR CORPORATE The Subcommittee identified 10 key researchTheater ques- 2, Exhibitradiation Hall oncology practices? AMBASSADORS of FOR hypofractionation. THEIR OUTSTANDING YEAR-ROUND LEADERSHIP AND tions to be addressed in the study: RADIXACT™ SYSTEM: INNOVATION PROMOTIONAL SUPPORT OF RADIATION ONCOLOGY. FOR EVERYDAY,10. CONFIDENCE Has there been IN a significant shift in the procure- • Thirty-seven percent of respondents, not includ- 1. Have the demographics of radiation oncologist EVERY OUTCOMEment and use of new of radiation therapy modali- ing recently graduated residents, report a change changed since the 2012 ASTRO Workforce Survey?12:30 p.m. - 1:30ties p.m. or techniques? in the structure of their compensation plan in the If yes, how? Company: Accuray Incorporated last three years. Contact: DianeThese Hobaugh key research questions will be addressed during 2. Is the radiation oncology workforce growing Phone:faster 408-789-4265an Education Session on Tuesday, September 26 • Two out of five respondents who report a change than demand? Are there sufficient positionsEmail: for [email protected] from 4:45 p.m. to 6:15 p.m. in Room 1 A/B titled The to the structure of their compensation plan had an new professionals in the field? CORPORATEASTRO 2017 Radiation AMBASSADORS Oncologist Workforce Study: increase in pay, while more than one-third experi- Monday, September 25, 2017 Past, Present, Future. Minh Tam Truong, MD, Boston enced a decrease. 3. Is the workforce balanced in terms of age, numberASTRO PROUDLYUniversity RECOGNIZES School ofTHE Medicine ONGOING will COMMITMENT present a segment OF OUR CORPORATE Theater 2, Exhibit Hall of residentsTuesday, entering Septemberthe field and number 26, 2017 of AMBASSADORSphysi- on radiation FOR THEIRoncologist OUTSTANDING demographics; YEAR-ROUND Trevor J. LEADERSHIPRoyce, To AND hear more about these findings, please join us for the RADIXACT™ SYSTEM: INNOVATION PROMOTIONAL SUPPORT OF RADIATION ONCOLOGY. cians retiring from practice? MD, MS, MPH, Harvard Radiation Oncology Program, session in Room 1 A/B on Tuesday September 26 from FOR EVERYDAY, CONFIDENCE IN Theater 1, Exhibit Hall will present supply and demand; Erli Chen, MS, 4:45 p.m. until 6:15 p.m. ● EVERY OUTCOME SURFACE4. GUIDEDIs there RADIATION sufficient geographic THERAPY: spread EVIDENCE to provide AND IMPLEMENTATIONCheshire Medical Center, will present technologies 12:30 p.m. - 1:30 p.m. access to careOF for MOTION patients who MANAGEMENT need radiation and practice patterns; and Claire Fung, MD, Beth Company: Accuray Incorporated 10:15 a.m. - 11: 15 a.m. Contact: Diane Hobaugh Contact: Parul Jani Phone: 408-789-4265 Company: Vision RT, Ltd Email: [email protected] CORPORATEPhone: AMBASSADORS + 44 208 349 6423 Monday, September 25, 2017 Email: [email protected]

ASTRO PROUDLY RECOGNIZESTheater THE ONGOING 1, Exhibit COMMITMENT Hall OF OURCORPORATE CORPORATE AMBASSADORS Theater 2, Exhibit Hall AMBASSADORS FOR THEIR OUTSTANDING YEAR-ROUND LEADERSHIP AND MRIDIAN LINAC: INITIAL CLINICAL EXPERIENCE RADIXACT™ SYSTEM: INNOVATIONTuesday, September 26, 2017 PROMOTIONAL SUPPORT OF RADIATION ONCOLOGY. FOR EVERYDAY, CONFIDENCE IN 12:30 p.m. - 1:30 p.m. Theater 1, Exhibit Hall EVERY OUTCOME Company: ViewRay SURFACE GUIDED RADIATION THERAPY: EVIDENCE AND IMPLEMENTATION 12:30 p.m. - 1:30 p.m. Contact: Meredith Johnson OF MOTION MANAGEMENT Company: Accuray Incorporated Phone: 408-396-2355 10:15 a.m. - 11: 15 a.m. Contact: Diane Hobaugh Email: [email protected] Contact: Parul Jani Phone: 408-789-4265 Company: Vision RT, Ltd Email: [email protected] Theater 2, Exhibit Hall Phone: + 44 208 349 6423 A NOVEL OPTION FOR BIOCHEMICALLY RECURRENT Email: [email protected] PROSTATE CANCER LOCALIZATION 12:30 p.m. - 1:30 p.m. Theater 1, Exhibit Hall Company: Blue Earth Diagnostics, Inc. Tuesday, September 26, 2017 MRIDIAN LINAC: INITIAL CLINICAL EXPERIENCE Contact: Maura Harrigan 12:30 p.m. - 1:30 p.m. Phone: 855-298-6461 Theater 1, Exhibit Hall Company: ViewRay Email: [email protected] SURFACE GUIDED RADIATION THERAPY: EVIDENCE AND IMPLEMENTATION Contact: Meredith Johnson OF MOTION MANAGEMENT Phone: 408-396-2355 EXHIBITOR DIRECTORY | ASTRO’S 59TH ANNUAL MEETING 49 10:15 a.m. - 11: 15 a.m. Email: [email protected] Contact: Parul Jani Company: Vision RT, Ltd Theater 2, Exhibit Hall 16 2017 - Annual Meeting - Exhibitor Listing (Tab 4 - IET and ISS).indd 49 8/18/2017 10:46:20 AM Phone: + 44 208 349 6423 A NOVEL OPTION FOR BIOCHEMICALLY RECURRENT Email: [email protected] PROSTATE CANCER LOCALIZATION 12:30 p.m. - 1:30 p.m. Theater 1, Exhibit Hall Company: Blue Earth Diagnostics, Inc. MRIDIAN LINAC: INITIAL CLINICAL EXPERIENCE Contact: Maura Harrigan 12:30 p.m. - 1:30 p.m. Phone: 855-298-6461 Company: ViewRay Email: [email protected] Contact: Meredith Johnson

Phone: 408-396-2355 EXHIBITOR DIRECTORY | ASTRO’S 59TH ANNUAL MEETING 49 Email: [email protected]

Theater 2, Exhibit Hall 2017 - Annual Meeting - Exhibitor Listing (Tab 4 - IET and ISS).indd 49 8/18/2017 10:46:20 AM A NOVEL OPTION FOR BIOCHEMICALLY RECURRENT PROSTATE CANCER LOCALIZATION 12:30 p.m. - 1:30 p.m. Company: Blue Earth Diagnostics, Inc. Contact: Maura Harrigan Phone: 855-298-6461 Email: [email protected]

EXHIBITOR DIRECTORY | ASTRO’S 59TH ANNUAL MEETING 49

2017 - Annual Meeting - Exhibitor Listing (Tab 4 - IET and ISS).indd 49 8/18/2017 10:46:20 AM ASTRO DAILY NEWS | Sunday/Monday

Honor World Cancer Research Day with the ROI By Emily Connelly, MA, ROI Governance and Research Administrator

his year, World Cancer Research Day is on At the booth, you can meet some of ROI’s researchers approaches to develop better predictive models and September 24. It’s fitting that a day dedicated to who are doing the groundbreaking work made possible decision support tools. Tincreasing awareness and recognition of cancer by the support of its generous donors. research efforts worldwide happens to coincide with • Tuesday, September 26 at 11:00 a.m. – Nitin Ohri, ASTRO 2017, which is radiation oncology’s premier event • Sunday, September 24 at 2:00 p.m. – Malolan S. MD, principal investigator of a clinical trial to for sharing the field’s latest research breakthroughs. Rajagopalan, MD, MBA, developer of the RadOnc determine if activity trackers and daily customized Stop by booth 3639 in the Innovation and Solution Toolbox app and website. step count goals can improve patients’ ability to Showcase to learn more about the Radiation Oncology tolerate concurrent radiochemotherapy. Institute (ROI) and its research aimed at heightening • Tuesday, September 26 at 10:00 a.m. – Todd the critical role of radiation therapy in the treatment McNutt, PhD, principal investigator of a study Established by the ASTRO Board of Directors in 2006, the of cancer. using big data analytics and machine learning ROI is an affiliated 501(c)(3) nonprofit foundation that relies on charitable gifts by donors like you to sustain its research and education programs. You can honor World Cancer Research Day by making a tax-deductible donation to the ROI at ASTRO 2017 to support important radiation oncology research to enhance practice and improve patient outcomes. ●

Don’t miss ASTRO keynote with Richard Zane, MD n Monday, Septem- Ober 25, from 9:15 a.m. to 10:15 a.m., Richard Zane, MD, will be pre- senting the first keynote address at ASTRO 2017 Richard Zane, MD in Ballroom 20. He will be discussing how disruptive new technology has begun to restructure front-line patient-doctor relationships. Dr. Zane is the George B. Boedecker Jr. and Boedecker Foundation Professor and Chair of the Department of Emergency Medicine at the University of Colorado School of Medicine; Pro- fessor of Health Administration at the University of Colorado Business School; Executive Director, Emergency Services, University of Colorado Health; and Chief Innovation Officer for the UCHealth System. Dr. Zane has extensive experience in designing and implementing systems of quality, emergency care, access and clinical integration, and has developed an international reputation for being able to apply modern industri- al engineering and informatics practices to health care and science. ●

Stay up to date on the #ASTRO17 Meeting!

17 ASTRO DAILY NEWS | Sunday/Monday

Grant Writing Workshop Brings Early-Career INDUSTRY-EXPERT THEATERS Investigators and Experienced Grant Writers Industry-Expert Theaters allow companies to present their note- worthy products and services through a live presentation. Seating Together to Hash Out Ideas is available on a first-come, first-served basis. The Industry-Expert Theater content and views expressed therein are those of the By Tyler Beck, PhD, ASTRO Scientific Program Officer exhibitor and not of ASTRO. The companies may offer you lunch or refreshments, PhD, from Northwestern University, gave which, if accepted, may subject you to being reported under an excellent introduction to grantsmanship the Federal Sunshine Act (the “Open Payments Program”) or with tips and hints on how to write basic other state laws. and translational science grants. Bernhard reminded attendees that Theaters 1 and 2 are located in the rear of the 3600 and 3700 aisles details matter in grant applications. He in the Innovation and Solution Showcase (Exhibit Hall) via the Hall C Entrance on the Ground Level. Room 14 A is located on the West urged prospective grantees to review the Mezzanine Level. full application guidelines prior to sub- mittal. He also shared that grant abstract and aims are critical, so researchers SUNDAY, SEPTEMBER 24 should spend extra time crafting these. 12:15 p.m. – 1:15 p.m. Reshma Jagsi, MD, PhD, from the Theater 1, Exhibit Hall Attendees at last summer’s science workshop. University of Michigan, then discussed 6 FACTS ON XOFIGO (RADIUM RA 233 DICHLORIDE) IN A applications for preclinical and clinical CHALLENGING ERA OF PROSTATE CANCER Bayer esearchers in radiation oncology are continuous- trials grants, as well as health services research and Company: ly on the cutting-edge of cancer research. With other research grants. Theater 2, Exhibit Hall Rthe recent increase in therapeutic combinations After the presentations, participants had the op- CYBERKNIFE® SYSTEM: CONFIDENCE TO DRIVE with immunotherapies and other targeted cancer portunity to ask questions and gain insight directly INNOVATION IN STEREOTACTIC RADIOTHERAPY drugs, radiation therapy research has become even from faculty members during small-group breakout Company: Accuray Incorporated more pivotal. Recent portfolio analyses have suggested sessions. For these hands-on sessions, attendees that researchers with projects focusing on radiation were asked to plan ahead by sending copies of the Session Room 14 A therapy have a high rate of success in securing grant abstract and specific aims of the grant they hope FUTURE DIRECTIONS: INCORPORATING IMMUNOTHERAPY IN THE LOCALLY ADVANCED TREATMENT SETTING funding. Despite this fact, the proportion of National to apply for in the near future. Faculty members Company: AstraZeneca Institutes of Health (NIH) funding being awarded to critiqued and gave suggestions on how to improve radiation oncology researchers remains relatively low. them during the breakout session. To encourage our early-career investigators to Workshops like this one are an integral part of MONDAY, SEPTEMBER 25 apply for more research funding, ASTRO held a training for our early-career investigators to become 12:30 p.m. – 1:30 p.m. four-hour Grant Writing Workshop on Saturday led leaders in the field. ASTRO is proud to have hosted Theater 1, Exhibit Hall by ASTRO members with successful grant portfolios the Grant Writing Workshop. Given its success, it is PRESENT AND FUTURE ROLE OF HYDROGEL SPACING IN and program officers at the NIH. likely that we’ll see similar workshops at future An- THE TREATMENT OF PROSTATE CANCER — 3 & 5 YEAR QOL During the faculty presentations, several classes of nual Meetings. For more information on workshops EVIDENCE AND SBRT EXPERIENCE grants were discussed. Eric Bernhard, PhD, and Susan and other professional development programs that Company: Augmenix Lim, PhD, both with the NIH, and David Gius, MD, ASTRO is running, visit www.astro.org/research. ● Theater 2, Exhibit Hall RADIXACT™ SYSTEM: INNOVATION FOR EVERYDAY, CONFIDENCE IN EVERY OUTCOME Employers, Job Seekers, Looking to Connect in Company: Accuray Incorporated San Diego? INDUSTRY SATELLITE SYMPOSIA The ASTRO Annual Meeting Career Center is conveniently located in Lobby D of the San Diego Convention Center. A touch-screen computer provides access to more than 55 jobs that have been posted online by em- ASTRO has reviewed and approved this symposium as ployers attending the ASTRO Annual Meeting, plus many other jobs listed by employers who are not specifi- appropriate for presentation. This symposium represents the cally interviewing applicants in San Diego. Look for the special Annual Meeting icon that identifies employers content and views of the supporters and are not part of the who will be in San Diego. Resumes and job listings can be posted online and hard copies can also be posted official ASTRO Annual Meeting. on the job board in Lobby D. A limited number of private interview rooms in the Convention Center may still be available for rent. Stop by the ASK ASTRO booth in Lobby D for more information. Visit the ASTRO Career SUNDAY, SEPTEMBER 24 Center online at www.astro.org/careercenter. 6:15 p.m. – 6:45 p.m. Dinner and Registration 6:45 p.m. – 8:15 p.m. Symposium NEW OPPORTUNITIES TO IMPROVE OUTCOMES IN LOCALLY ADVANCED, UNRESECTABLE LUNG CANCER: INTEGRAT- Save steps by using the ING IMMUNOTHERAPY INTO A MULTIMODAL TREATMENT APPROACH Interactive Map Kiosks Hilton San Diego Bayfront, Sapphire AB Interactive Map Kiosks are interactive touch screens conve- Dinner will be provided. niently located at the main entrances of the Innovation and For more information or to register, please visit www.peerviewpress. com/ImmunoRad17 or contact [email protected]. Solution Showcase and Poster Hall. Use these touch screens to help you easily locate an exhibitor, product or poster. A direct This activity is supported by an independent educational walking path will be provided to the exhibitor’s booth or poster grant from AstraZeneca. you wish to visit. This CME activity is jointly provided by Medical Learning Institute and PVI, PeerView Institute for Medical Education.

18 ASTRO DAILY NEWS | Sunday/Monday

Survivor Circle: It’s All About the Patients ASTRO recognizes patients and the organizations that support them

ach year, as a way to honor cancer survivors, ASTRO awards the Survi- vor Circle Award to a cancer survivor and two Survivor Circle Grants to Epatient support organizations. The Survivor Circle Award recognizes a cancer survivor who has dedicated his or her time and energy in service and support of the local community. The Survivor Circle Grants are financial assistance presented to two nonprofit organizations to support their programs that help those affected by cancer. Please stop by Lobby D, Ground Level, to talk with representatives of this year’s Survivor Circle grant recipients.

Survivor Circle Award “As soon as I could get back to vol- ASTRO has selected Rocky Craig, a resi- unteering after my treatment, I did it,” dent of La Mesa, California, to receive the says Craig. “It takes away any concern 2017 ASTRO Survivor Circle Award. Craig about what’s going on with me. I have will be presented with this award, along a wonderful day when I’m working out with $1,000, during the Awards Ceremony there, every day.” on Tuesday from 10:15 a.m. to 11:30 a.m. in Kristi Vetrand, the cancer patient Ballroom 20. Craig is battling lung cancer navigator at the David and Donna Long Campers and counselors from Seany’s Camp Reach for the Sky but still volunteers his time as a shuttle Center for Cancer Treatment, agrees. bus driver for Sharp Grossmont Hospital. “Rocky always has a smile and positive hold our Annual Meeting. This year’s The organization’s chief executive attitude. He provides support, comfort grantees—the Cancer Angels of San officer and his wife founded The Seany and a listening ear to those who need it. Diego and The Seany Foundation—are Foundation in 2006 to honor their son, Even after he completed treatment, he eminently worthy recipients.” Sean Robins, who passed away after bat- came back to visit with patients he knew Cancer Angels of San Diego was tling Ewing sarcoma. Its initial goal was were still in treatment, to check on them founded in 2007 after founder and pres- to fund pediatric cancer research but now and provide hope and encouragement.” ident Eve Beutler met a single mother focuses on projects, such as overnight Even in receiving the award, Craig with stage IV breast cancer who was camps, that help kids cope with cancer. defers the honor, pointing to the staff at having trouble making rent while she Known as Seany’s Camp Reach for the the hospital where he was treated. was receiving treatment. Beutler decided Sky, these free camps are for kids with “It’s very humbling to receive this to start a nonprofit aimed at providing cancer and their siblings. They also host recognition,” Craig said. “When you’re a financial assistance to stage IV cancer weekend camps for teen patients, survivors volunteer, you’re not looking for recogni- patients for necessities that health insur- and siblings, as well as camps for families tion. You do it because you want to help ance doesn’t cover, like rent or mortgage with a parent with cancer and families people. But I think the people who work payments, groceries and gas. who have lost a parent or child to cancer. at Sharp Grossmont need this award. Ev- “This grant will help us get school The Survivor Circle award and grants ery day, they make you feel comfortable. supplies and clothing for children whose are made possible through generous do- It takes a special person to do that.” parents are battling cancer and would nations from exhibiting companies that Tuesday’s keynote speaker, Lucy not be able to afford back-to-school shop- participate in the Passport Program. This Rocky Craig, 2017 ASTRO Survivor Circle Award Kalanithi, MD, who is a doctor-turned- ping otherwise,” said Beutler. year’s Passport Program participants are: winner caregiver, will present the Survivor Circle Every month, Cancer Angels of San Alliance Oncology, Augmenix, Blue Earth “ASTRO is privileged to present this Award to Rocky on behalf of ASTRO. Diego pays for the rent or mortgage pay- Diagnostics, CIVCO, Hologic, Mevion, Mi- meaningful award to such an inspiring ments, and gives a grocery gift card and rada, Sun Nuclear Corporation, Vertual, man. Rocky Craig could have been bitter Survivor Circle Grants gas gift card, to between 25 and 30 San ViewRay and Vision RT. about his diagnosis, having led a healthy ASTRO will award its Survivor Circle Diego County families, many of whom life. Instead, he has found courage and grants to two San Diego-based cancer are headed by single mothers battling ASTRO’s RTAnswers.org Patient actively shares his positivity with other support charities: Cancer Angels of San stage IV cancer. Stories patients battling cancer,” said ASTRO Diego and The Seany Foundation. Each Beutler said many of the cancer pa- In order to communicate the importance President-elect Paul M. Harari, MD, FAS- organization will receive an $8,500 grant tients they work with were middle-class of access to treatments and quality care, TRO. “Despite his ongoing treatment for to support their programs for those who before their diagnoses—but not being ASTRO has launched an online library of lung cancer, he continues to volunteer have been affected by cancer. Repre- able to work and not having long-term patient stories on its patient education for the hospital where he is being treat- sentatives from each organization are disability insurance has created financial website, RTAnswers.org. ed—and his story and encouragement attending the Annual Meeting and will devastation for these families. Do you know a patient who has a com- helps spread hope to others.” spend time in the Survivor Circle area “Without our help, most of our clients pelling story to share with ASTRO? ASTRO Craig began volunteering at Sharp by the Ask ASTRO booth to talk with would be homeless,” said Beutler. “We is looking to add more patient voices to Grossmont three years ago—even before attendees about their work with patients have gotten many families that were pre- this collection, which can be accessed at his December 2016 diagnosis of Stage III and caregivers. viously living in their cars into homes.” www.rtanswers.org/PatientStories. These lung cancer. Following a seven-year stint “The Survivor Circle Grant Program The Seany Foundation’s mission is to stories may also be used as a resource for in the Major Leagues, playing for ball is ASTRO’s way of recognizing the great fund meaningful projects that enhance advocacy, public awareness and clinical clubs like the Kansas City Royals, Hous- work that these nonprofit organizations the lives of children and families affected guideline development efforts. ton Astros and even his home team, the do to support cancer patients and their by cancer, mainly through day, overnight If you know a patient who would San Diego Padres, Craig spent 28 years families,” said ASTRO President Brian D. and weekend camps designed for pedi- like to share their cancer story with us, as a UPS delivery truck driver. Craig now Kavanagh, MD, MPH, FASTRO. “We are atric cancer patients and their siblings; please give them the link to the Share puts those driving skills to good use in honored to give back to the organizations children of cancer patients; or children Your Story Form at www.rtanswers.org/ his role at Sharp Grossmont. that work in the communities where we who have lost a family member to cancer. shareyourstory. ● 19 B:10.75” T:10.5” S:10”

Dimensions: 10.5” x 14”

Visit the Merck Booth and Learn More About B:14.25” S:13.5” KEYTRUDA T:14”

• Approved indications

• Resources for health care professionals

• The Merck Access Program

• KEY+YOU Patient Support Program

KPTCONUS-02827_ASTRO_Journal_AD_PP02.indd 1 8/31/17 2:16 PM